




樂普生物科技股份有限公司
LEPU BIOPHARMA CO.,LTD.

(A joint stock company incorporated in the People's Republic of China with limited liability)

Stock Code: 2157



2025
INTERIM REPORT

CONTENTS

2	CORPORATE INFORMATION
4	FINANCIAL SUMMARY
5	MANAGEMENT DISCUSSION AND ANALYSIS
23	OTHER INFORMATION
29	REPORT ON REVIEW OF INTERIM FINANCIAL INFORMATION
30	INTERIM CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME
31	INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION
33	INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
34	INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
35	NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION
55	DEFINITIONS AND GLOSSARY OF TECHNICAL TERMS

CORPORATE INFORMATION

EXECUTIVE DIRECTORS

Dr. Pu Zhongjie (蒲忠傑) (*Chairman*)
Dr. Sui Ziyue (隋滋野) (*Chief Executive Officer*)

NON-EXECUTIVE DIRECTORS

Ms. Pu Jue (蒲珏)
Ms. Qin Yiran (秦怡然) (*appointed with effect from June 27, 2025*)
Mr. Yang Hongbing (楊紅冰) (*retired with effect from June 27, 2025*)

INDEPENDENT NON-EXECUTIVE DIRECTORS

Mr. Zhou Demin (周德敏)
Mr. Yang Haifeng (楊海峰)
Mr. Fengmao Hua (華風茂)

SUPERVISORS

Mr. Xu Yang (徐揚)
Mr. Yang Ming (楊明)
Ms. Zhao Lixuan (趙力萱)

AUDIT COMMITTEE

Mr. Fengmao Hua (華風茂) (*Chairman*)
Mr. Yang Haifeng (楊海峰)
Ms. Pu Jue (蒲珏)

REMUNERATION AND APPRAISAL COMMITTEE

Mr. Yang Haifeng (楊海峰) (*Chairman*)
Mr. Fengmao Hua (華風茂)
Dr. Pu Zhongjie (蒲忠傑)

NOMINATION COMMITTEE

Mr. Zhou Demin (周德敏) (*Chairman*)
Mr. Yang Haifeng (楊海峰)
Ms. Pu Jue (蒲珏) (*appointed with effect from June 27, 2025*)
Dr. Pu Zhongjie (蒲忠傑) (*retired with effect from June 27, 2025*)

STRATEGY COMMITTEE

Dr. Pu Zhongjie (蒲忠傑) (*Chairman*)
Dr. Sui Ziyue (隋滋野)
Mr. Zhou Demin (周德敏)

JOINT COMPANY SECRETARIES

Ms. Li Yunyi (李昀軼)
Ms. Lai Siu Kuen (黎少娟) (*FCG, HKFCG*)

AUTHORISED REPRESENTATIVES

Dr. Pu Zhongjie (蒲忠傑)
Ms. Lai Siu Kuen (黎少娟) (*FCIS, HKFCG*)

AUDITOR

Ernst & Young
*Certified Public Accountants and
Registered Public Interest Entity Auditor*
27/F, One Taikoo Place
979 King's Road
Quarry Bay
Hong Kong

HONG KONG LEGAL ADVISER

Herbert Smith Freehills Kramer
23/F, Gloucester Tower
15 Queen's Road Central
Hong Kong

PRC LEGAL ADVISER

Zhong Lun Law Firm
23-31/F, South Tower of CP Center
20 Jin He East Avenue
Chaoyang District
Beijing
PRC

H SHARE REGISTRAR AND TRANSFER OFFICE

Computershare Hong Kong Investor Services Limited
Shops 1712-1716, 17th Floor
Hopewell Centre
183 Queen's Road East
Wan Chai
Hong Kong

CORPORATE INFORMATION

PRINCIPAL PLACE OF BUSINESS IN HONG KONG

Room 1918, 19/F
Lee Garden One
33 Hysan Avenue Causeway Bay
Hong Kong

PRINCIPAL BANKS

**Industrial and Commercial Bank of China
Shanghai Xinzhuang Industrial District Sub-branch**

No. 3800 Jindu Road
Minhang District
Shanghai
China

**Agricultural Bank of China Shanghai
Branch Minhang Sub-branch**

No. 68 South Shuiqing Road
Minhang District
Shanghai
China

**China Merchants Bank Shanghai
Minhang Sub-branch**

No. 365, Xinsong Road
Minhang District
Shanghai
China

HEAD OFFICE AND PRINCIPAL PLACE OF BUSINESS IN THE PRC

No. 651, Lianheng Road
Minhang District, Shanghai
PRC

STOCK CODE

02157

COMPANY WEBSITE

www.lepubiopharma.com

FINANCIAL SUMMARY

	As at June 30 2025 RMB'000 (Unaudited)	As at December 31 2024 RMB'000 (Audited)
Total assets	2,361,606	2,280,685
Total liabilities	1,649,811	1,598,882
Total equity	711,795	681,803

	As at June 30 2025 RMB'000 (Unaudited)	As at June 30 2024 RMB'000 (Unaudited)
Revenue	465,942	133,283
Cost of sales	(27,403)	(21,042)
Gross profit	438,539	112,241
Other income	1,964	651
Selling and marketing expenses	(97,879)	(43,789)
Administrative expenses	(55,376)	(30,844)
Research and development expenses	(202,243)	(216,610)
Fair value changes on financial liabilities at fair value through profit or loss	(16,957)	(124)
Other losses, net	(25,067)	(5,561)
Operating income/(loss)	42,981	(184,036)
Finance costs, net	(7,445)	(5,893)
Share of loss of investments accounted for using the equity method	(6,234)	(7,037)
Profit/(loss) before income tax	29,302	(196,966)

MANAGEMENT DISCUSSION AND ANALYSIS

OVERVIEW

We are an innovation-driven biopharmaceutical company focusing on oncology therapeutics, in particular, targeted therapy and oncology immunotherapy, with a strong China foundation and global vision. Since our establishment, we have been dedicated to developing innovative ADCs through our comprehensive and advanced ADC technology development platform and we aim to develop optimal and innovative drugs to better serve the unmet medical needs of cancer patients. We have an integrated end-to-end capability across drug discovery, clinical development, CMC and GMP-compliant manufacturing, encompassing all critical functions of the biopharmaceutical value chain. We are committed to continuously developing a market-differentiating pipeline by fully integrating our independent innovation capabilities and strategic collaborations. Concurrently, we are dedicated to exploring synergistic therapeutic approaches on the basis of the continuous enrichment of our product pipeline. We have established and are progressively expanding our internal manufacturing capabilities, driven by the business needs stemming from the upcoming commercialization of our ADC candidates.

We have strategically designed our pipeline with a range of oncology products. As of the date of this report, for clinical-stage candidates, we have (i) one clinical/commercialization-stage drug candidate; (ii) nine clinical-stage drug candidates, including one co-developed through a joint venture; and (iii) three clinical-stage combination therapies of our candidates. One of our drug candidates has obtained marketing approval with respect to two of its targeted indications, with clinical trials for other indications ongoing. Among the nine clinical-stage drug candidates, seven are targeted therapeutics and two are immunotherapeutics, which are an oncolytic virus drug and T cell agonistic antibody. MRG003 was granted BTM, ODD and FTD on NPC from the FDA and BTM from the CDE. MRG002 was granted ODD on GC/GEJ from the FDA. CMG901 was granted FTD and ODD in GC/GEJ from the FDA, and obtained BTM from CDE. MRG004A was granted ODD and FTD by the FDA for the treatment of PC. CG0070 was granted BTM from the CDE and FDA. In addition, MRG003 and MRG006A have obtained IND clearance from the FDA. We continuously strive to build up and develop novel technology platforms as innovative engines for the Company.

We aim to commercialize our pipeline products in China through dedicated sales and marketing forces, while attaining international market reach through strategic partnerships. As of the end of the Reporting Period, the Company has achieved significant milestones in the monetisation of our R&D capabilities through commercialization and BD activities: PUYOUHENG (Pucotenlimab Injection) has completed the full commercialization process and is currently under a rapid sales growth, and two other products, CMG901 and MRG007 have also been licensed out through our BD activities. Notably, CMG901's global rights have been licensed to AstraZeneca, and MRG007's rights for regions outside Greater China have been licensed to ArriVent. These accomplishments have established a solid foundation for the Company's future commercialization of ADC products and global cooperations. The Company has established end-to-end commercialization capabilities in the domestic market, while positioning itself as a global biotech company with growing engagement in international R&D and strategic partnerships.

MANAGEMENT DISCUSSION AND ANALYSIS

PRODUCT PIPELINE

The following chart illustrates our pipeline and summarizes the development status of our clinical-stage candidates:

	Drug Candidates	Indications	Status ²					
			Preclinical	Phase Ia	Phase Ib	Phase II	Pivotal/Phase III	NDA
ADC	MRG003* EGFR-targeted ADC	NPC	≥2L NPC (nasopharyngeal cancer)	Mono				
				Combo				
		HNSCC	≥2L HNSCC (head and neck squamous cell carcinoma)	Mono				
			1L HNSCC	Combo				
	MRG004A TF-targeted ADC	TF-positive (tissue factor positive) advanced or metastatic solid tumors						
	MRG002* HER2-targeted ADC	BC	BC (breast cancer) HER2 (human epidermal growth factor receptor 2) over-expressing with liver metastasis	Mono				
			BC HER2-positive	Mono				
		UC	HER2-expressing solid tumor	Combo				
	MRG001 CD20-targeted ADC	NHL (non-Hodgkin's lymphoma)		Mono				
	MRG006A GPC3-targeted ADC	Solid tumor						
OV	MRG007 CDH17-targeted ADC ³	Solid tumor						
	CMG901 CLDN18.2-targeted ADC ⁴	G/GEJ carcinoma (gastric and gastroesophageal junction carcinoma) and other solid tumors						
	CG0070 ⁵ Oncolytic virus	BCG-unresponsive NMIBC (bacillus calmette-guérin unresponsive non-muscle invasive bladder cancer)		Mono				
				Combo				
Immunology	PUYOUHENG (Pucotenlimab Injection)* Anti-PD-1 mAb	≥2L Melanoma ¹						
		≥2L MSI-H/dMMR (high levels of microsatellite instability/deficient mismatch repair) solid tumors ³						
	CTM012 T cell agonistic mAb ⁶	Solid tumor						

Notes:

- * denotes the Core Products.
- Unless otherwise stated, the progress shown under the "Status" column refers to the clinical development progress of the relevant drug candidate and combination therapy in China.
- In 2022, we obtained from the NMPA conditional marketing approval for PUYOUHENG (Pucotenlimab Injection) on MSI-H/dMMR and inoperable or metastatic melanoma, respectively. We are conducting confirmatory Phase III clinical studies on the first-line MSI-H/dMMR metastatic colorectal cancer and the first-line stage IV (M1c) melanoma respectively.
- In February 2023, KYM has entered into a global exclusive out-license agreement with AstraZeneca to grant an exclusive global license for research, development, registration, manufacturing and commercialization of CMG901 to AstraZeneca. For details, please refer to the Company's announcements dated February 23, 2023 and April 15, 2024.
- On January 22, 2025, the Company has entered into an exclusive license agreement with ArriVent, pursuant to which ArriVent has been granted an exclusive license to develop and commercialize MRG007 outside the Greater China Region. For details, please refer to the Company's announcement dated January 22, 2025.
- On August 1, 2025, the Company has entered into the Intellectual Property Assignment and Licence Agreement with Excalipoint. Pursuant to this agreement, the global rights of CTM012 has been licensed to Excalipoint and the Company holds a 10% equity interest in Excalipoint. For details, please refer to the Company's announcement dated August 1, 2025.

MANAGEMENT DISCUSSION AND ANALYSIS

BUSINESS REVIEW

Commercialization

During the Reporting Period, the Group achieved a significant growth in revenue, recording a total revenue of approximately RMB465.9 million, which was approximately 3.5 times of the revenue of the same period in 2024 at RMB133.3 million. For licensing activities, the Group has recognized approximately RMB309.0 million in revenue primarily from the out-licensing of MRG007. In the first half of 2025, the Group recorded a revenue of approximately RMB150.6 million for the sales of PUYOUHENG (Pucotenlimab Injection), marking a significant increase of 58.8% from the sales recorded in the same period in 2024 (for the six months ended June 30, 2024: approximately RMB94.8 million). In addition, the Group recognized approximately RMB6.3 million in revenue for the provision of CDMO services (for the six months ended June 30, 2024: approximately RMB17.8 million).

- As of June 30, 2025, the Group recorded revenue of approximately RMB309.0 million generated primarily through the out-licensing of MRG007. We remain committed to advancing our global licensing strategy and actively carry out out-licensing collaborations. In January 2025, the Company entered into an exclusive licensing agreement with ArriVent, pursuant to which the Company has granted ArriVent exclusive rights to develop, manufacture and commercialize MRG007, our second product candidate successfully licensed out following CMG901, outside of Greater China. Under the terms of the agreement, the Company is eligible to receive up to US\$1.2 billion in total upfront payment, development, regulatory and sales milestones payments, together tiered royalties on net sales. This transaction demonstrates the Company's growing expertise in global partnership strategies, as it continues to accumulate experience in seeking strategic partners worldwide to advance its pipeline assets across international markets.
- We have built a highly efficient sales and marketing team for our commercialized product, PUYOUHENG (Pucotenlimab Injection). Our commercialization team is mainly responsible for developing strategies for product promotion, product positioning and brand management, establishing a good brand image in the market through academic promotion activities and product education to increase product awareness among leading physicians and the patient population. In April 2023, pucotenlimab has been successfully included in the 2023 CSCO and CSGO Guidelines for melanoma and MSI-H/dMMR solid tumors, which represents a high degree of recognition from clinical KOL's.

In terms of the establishment of sales channels, we actively develop cooperative relationships with various business channel partners. As of June 30, 2025, we have completed the tendering process on the procurement platform in 28 provinces of the PRC. We have covered approximately 118 cities in the PRC through various sales channels, and we will further expand our sales network.

- Furthermore, we have strategically leveraged our surplus capacity to provide CDMO services to Lepu Medical and/or its subsidiaries for their development of GLP-1 and related products. These efforts yielded CDMO services related revenue of approximately RMB6.3 million for the six months ended June 30, 2025.

MANAGEMENT DISCUSSION AND ANALYSIS

In the first half of 2025, the Group remained focused on the research and development of its drug candidates, while continuously assessing market demand and competitive landscape relating to the range of oncology therapeutics and the broad spectrum of indications covered by its drug candidates, in order to maximize the competitiveness of its products pipeline. A description of the progress made and the latest status in respect of the Group's drug candidates for the first half of 2025 and up to the date of this interim report is as follows:

MRG003

MRG003 is an ADC comprised of an EGFR-targeted mAb conjugated with the potent microtubulin disrupting payload MMAE via a vc linker. It binds specifically with high affinity to human EGFR on the surface of tumor cells, releases the potent payload upon internalization and lysosomal protease cleavage of the linker, and results in tumor cell death.

MRG003 is currently under NDA review by the CDE of NMPA for the treatment of R/M NPC. Meanwhile, we are concurrently conducting a Phase III clinical study on HNSCC. We are also further exploring the potential of MRG003 through its combination with immuno-oncology which may move forward to become an earlier line treatment therapy and bring clinical benefits to more patients.

- **NPC:** MRG003 is under NDA review for the treatment of R/M NPC and has also been granted priority review by the CDE of NMPA. The authority is currently proceeding with the clinical and pharmaceutical evaluation of MRG003 in an orderly manner. The encouraging data of the pivotal Phase IIb clinical study for the treatment of R/M NPC was read out as "late breaking abstract (LBA)" for oral presentation at the ASCO Congress 2025. As of 30 June 2024, MRG003 demonstrated a significant improvement in PFS compared to chemotherapy, with median PFS of 5.82 months and 2.83 months respectively, and the risk of disease progression/death was reduced by 37%. Additionally, ORR was 30.2% in the MRG003 group, as compared with 11.5% in the chemotherapy group. As of December 31, 2024, a favourable trend of OS has been noticeably observed in the MRG003 group, with median OS of 17.08 months, as compared with 11.99 months in each of the two groups, mOS is not mature.

We are also conducting the Phase III clinical trial of combination therapy with MRG003 and pucotenlimab on R/M NPC. The combination therapy demonstrated promising data in phase II clinical trial on R/M NPC, which will be presented at the ESMO Congress 2025.

HNSCC: As of June 30, 2025, we are conducting a randomized, open-label, multicenter Phase III clinical study on HNSCC.

In terms of combination therapy with MRG003 and pucotenlimab, we are currently conducting the Phase II clinical trial on HNSCC, which has moved to first-line treatment, and the encouraging data in phase II clinical trial will be presented at the ESMO Congress 2025. In addition, the European Medicines Agency (EMA) granted Clinical Trial Authorization (CTA) approvals for the Phase II clinical trial targeting LA-SCCHN in June 2025, and we will initiate the clinical trial in the second half of 2025.

- **Warning under Rule 18A.08(3) of the Listing Rules:** There is no assurance that the MRG003 will ultimately be successfully developed and marketed by the Company. Shareholders and our potential investors are advised to exercise caution when dealing in the Shares.

MANAGEMENT DISCUSSION AND ANALYSIS

MRG004A

MRG004A is a novel TF-targeted site-specifically conjugated ADC. We have completed the Phase I clinical study on solid tumors in China and the encouraging Phase Ib expansion data on PC will be presented at the ESMO Congress 2025. Protocol communication with CDE for the pivotal clinical trial of MRG004A has been completed, and we have entered the Phase III clinical trial stage in August 2025.

- **Warning under Rule 18A.08(3) of the Listing Rules:** There is no assurance that the MRG004A will ultimately be successfully developed and marketed by the Company. Shareholders and our potential investors are advised to exercise caution when dealing in the Shares.

MRG002

MRG002 is an innovative ADC targeting HER2, a molecular target abnormally over-expressed in many cancer types including BC, UC and GC/GEJ. Our clinical development strategy for MRG002 in China aims at realizing the efficacy potential of MRG002 in various prevalent malignancies, especially for second- or later-line systemic therapy of BC. Registrational clinical trials in the aforementioned indications are ongoing. We are constantly exploring the potential of MRG002 through its combination with immuno-oncology by conducting clinical studies which aim to target more patients in early stage and provide more options to fulfill the unmet medical needs.

– Monotherapy

HER2 over-expressing BC: We have completed the pivotal Phase II clinical trial on HER2 over-expressed BC with liver metastasis in China and have observed encouraging data. As of June 30, 2025, we are conducting a Phase III clinical study on HER2-positive BC.

– Combination Therapy

MRG002 + PUYOUHENG (Pucotenlimab Injection): As of June 30, 2025, we have completed the Phase II trial of combination therapy with MRG002 and pucotenlimab in the treatment of HER2-expressing solid tumors, which has moved to first-line treatment, and protocol communication for phase III clinical trial has been completed. We have observed encouraging data on UC.

- **Warning under Rule 18A.08(3) of the Listing Rules:** There is no assurance that the MRG002 will ultimately be successfully developed and marketed by the Company. Shareholders and our potential investors are advised to exercise caution when dealing in the Shares.

MRG001

MRG001 is a clinically advancing CD20-targeted ADC which addresses the medical needs of B cell NHL patients with either primary drug resistance to rituximab or acquired drug resistance to the combination therapy of rituximab and standard chemotherapies. We have completed the Phase Ib dose expansion study of MRG001 in China and have observed encouraging preliminary data on DLBCL. Meanwhile, the study of MRG001 in combination with BTK inhibitors for patients with DLBCL is ongoing, with interim data expected to be presented at the 67th ASH Annual Meeting.

MANAGEMENT DISCUSSION AND ANALYSIS

- **Warning under Rule 18A.08(3) of the Listing Rules:** There is no assurance that MRG001 will ultimately be successfully developed and marketed by the Company. Shareholders and our potential investors are advised to exercise caution when dealing in the Shares.

MRG006A

MRG006A is a novel topoisomerase I inhibitor-based GPC-3 ADC candidate with global first-in-class potential, which has been developed based on our Hi-TOPI ADC platform. We are currently advancing Phase I clinical trial in China. Moreover, we received IND clearance from the FDA in January 2025. In pre-clinical studies, MRG006A resulted in a robust and dose-dependent tumor growth inhibition on multiple CDX models and HCC PDX models. In the meantime, MRG006A also demonstrated good tolerability in the exploratory toxicology study.

- **Warning under Rule 18A.08(3) of the Listing Rules:** There is no assurance that MRG006A will ultimately be successfully developed and marketed by the Company. Shareholders and our potential investors are advised to exercise caution when dealing in the Shares.

MRG007

MRG007, a novel CDH17-targeting ADC, has shown robust antitumor activity in preclinical models of GI cancers and a favorable therapeutic index based on IND enabling studies. We received IND approval from the NMPA in June 2025 and are currently conducting a Phase Ia clinical trial for the treatment of unresectable locally advanced or metastatic solid tumors. The pre-clinical data of MRG007 was presented at the AACR Annual Meeting in April 2025.

On January 22, 2025, the Company has entered into an exclusive license agreement with ArriVent to develop and commercialize MRG007. Under the terms of the agreement, the Company has granted ArriVent exclusive rights to develop, manufacture and commercialize MRG007 outside of Greater China. The one-time upfront and near-term milestone payments amount to US\$47 million and the Company is eligible to receive up to US\$1.16 billion in development, regulatory and sales milestones and tiered royalties on net sales outside of Greater China. As of June 30, 2025, we have received the upfront payment.

- **Warning under Rule 18A.08(3) of the Listing Rules:** There is no assurance that MRG007 will ultimately be successfully developed and marketed by the Company. Shareholders and our potential investors are advised to exercise caution when dealing in the Shares.

CMG901

CMG901 is a CLDN18.2-targeting ADC comprising a CLDN18.2-specific antibody, a cleavable linker and a toxic payload, MMAE. It is the first CLDN18.2 targeting ADC to have received IND clearance both in China and the U.S. CLDN18.2 is selectively and widely expressed in GC, PC and other solid tumors, which makes it an ideal tumor target for therapeutic development. It is being co-developed by us and Keymed through a joint venture, KYM. In February 2023, AstraZeneca was granted the exclusive global license for the research, development, registration, production, and commercialization of CMG901 (AZD0901). As of the date of this report, AstraZeneca has initiated multiple clinical studies on CMG901 (AZD0901) for the treatment of advanced solid tumors, with indications including gastric cancer, pancreatic cancer, and biliary tract cancer.

MANAGEMENT DISCUSSION AND ANALYSIS

In the first half of 2025, AstraZeneca continued to advance a Phase II, open-label, multi-center study aimed at evaluating the safety, tolerability, efficacy, pharmacokinetics, and immunogenicity of AZD0901 as a monotherapy and in combination with other anti-tumor drugs in patients with Claudin 18.2-positive advanced solid tumors. Additionally, AstraZeneca is also progressing a Phase III, multi-center, open-label, sponsor-blinded randomized study designed to compare the safety and efficacy of AZD0901 monotherapy versus investigator's choice of treatment in adult patients with Claudin 18.2-positive second-line or later advanced/metastatic gastric adenocarcinoma or gastroesophageal junction adenocarcinoma. As of the date of this report, both clinical studies are currently in the patient enrollment phase.

- **Warning under Rule 18A.08(3) of the Listing Rules:** There is no assurance that CMG901 will ultimately be successfully developed and marketed by the Company. Shareholders and our potential investors are advised to exercise caution when dealing in the Shares.

CG0070

CG0070 is an oncolytic adenovirus for the treatment of BCG unresponsive bladder cancer patients and is currently in a MRCT Phase III clinical study conducted by our U.S. partner, CG Oncology. The latest encouraging data observed has been orally presented in the 120th American Urological Association Annual Meeting in April 2025. 75.5% of patients achieved CR at any time after receiving treatment with CG0070 as monotherapy. The median DOR has not been reached but exceeds 28 months as of the data cut-off of March 14, 2025.

We in-licensed CG0070 from CG Oncology and were granted the rights to develop, manufacture and commercialize it in Mainland China, Hong Kong and Macau. As of June 30, 2025, We have completed the Phase I clinical trial in China and are currently engaged in protocol communication with the CDE regarding the domestic pivotal bridging clinical trial. For the combination therapy of CG0070 with PUYOUHENG (Pucotenlimab Injection), we received an IND approval from the NMPA for its Phase I trial in the treatment of patients with BCG-unresponsive NMIBC.

In January 2025, CG0070 was granted BTB by the CDE for the treatment of BCG unresponsive bladder cancer patients, which have relapsed or are refractory to prior approved therapies, and this designation signified the innovativeness and the potential of CG0070 to fulfill the unmet medical needs.

- **Warning under Rule 18A.08(3) of the Listing Rules:** There is no assurance that CG0070 will ultimately be successfully developed and marketed by the Company. Shareholders and our potential investors are advised to exercise caution when dealing in the Shares.

PUYOUHENG (Pucotenlimab Injection)

- PUYOUHENG (Pucotenlimab Injection) is a humanized IgG4 mAb against human PD-1, which can antagonize the PD-1 signal to restore the capability of the immune cells to kill cancer cells through blocking PD-1 binding to their ligands PD-L1 and PD-L2, and which has been commercialized for treating MSI-H/dMMR and inoperable or metastatic melanoma since the second half of 2022. In April 2023, two indications were included into the 2023 CSCO Guideline, which are pucotenlimab as \geq second-line treatment of MSI-H/dMMR colorectal cancer and solid tumors, and pucotenlimab as second-line treatment of melanoma. Moreover, Pucotenlimab for treatment of advanced and recurrent MSI-H/dMMR gynecological cancer was included into the 2023 CSGO Guideline. Pucotenlimab demonstrated robust antitumor activity in patients (pts) with MSI-H/dMMR, based on findings from the phase II study, and we presented the long-term survival results and the updated safety profile at the ASCO Annual Meeting 2025.

MANAGEMENT DISCUSSION AND ANALYSIS

- o **MSI-H/dMMR solid tumors:** We are conducting an open label, multi-center and randomized Phase III clinical trial on the first-line MSI-H/dMMR metastatic colorectal cancer as a confirmatory clinical study for the conditional marketing approval as of June 30, 2025.
- o **Melanoma:** We are conducting an open label, multi-center and randomized Phase III clinical trial on the first-line treatment of subjects with stage IV (M1c) melanoma as a confirmatory clinical study for the conditional marketing approval as of June 30, 2025.

Innovation platforms

We continuously strive to build up and develop novel technology platforms as innovative engines for the Company. We have developed multiple innovative linker-payload platforms for ADC drug candidates, including the Hi-TOPI ADC platform and other early-stage platforms. During the Reporting Period, our innovative ADC platforms have achieved significant progress. Based on these innovation platforms, we have generated two ADC candidates, which are MRG006A with global first-in-class potential and MRG007 with global best-in-class potential, all of which have shown encouraging pre-clinical data and received IND approvals in China. Pre-clinical data of MRG007 was presented at the AACR Annual Meeting in April 2025.

- **Hi-TOPI ADC platform:** The Hi-TOPI ADC platform for ADC is featured by: (i) Linker designed with optimal hydrophilicity to ensure robust developability and favorable druggability, which is highly stable in circulation and efficient in intracellular payload release; (ii) Payload, which has good potency when compared to competitors (it is not a substrate for Pgp, and therefore it has a great potential of overcoming drug resistance); (iii) ADCs utilizing the novel linker-payload have demonstrated strong anti-tumor activity in PDX of multiple tumor types and also shown excellent safety profile and good tolerance in monkeys; and (iv) improved therapeutic window.

Using the novel linker-payload platform, we have developed MRG006A, which is an ADC candidate with global first-in-class potential and is currently undergoing Phase I clinical trial in China.

- **Bispecific ADC:** By harnessing bispecific ADC technology to co-engage targets A and B, bsAb ADCs can significantly expand therapeutic reach across key indications, including lung cancer and beyond.
- **Next generation PD-1:** PD-1 × cytokine bispecific antibodies are designed to overcome both primary and acquired resistance to existing PD-1 therapies. Anchored by the PD-1-plus immuno-oncology platform, this approach has the potential to markedly improve objective response rates (ORR) and extend overall survival (OS). It spans a wide spectrum of tumor types and may offer meaningful survival benefits when combined with ADCs, translating into meaningful survival gains for patients.
- **T cell engager platform:** Our proprietary T cell engager platform – TOPAbody – is characterized by (i) simultaneous activation of both TCR signaling and the co-stimulatory pathway, intended to unlock the full potential of T cells, and (ii) restricted activity within the tumor microenvironment.

MANAGEMENT DISCUSSION AND ANALYSIS

Manufacturing Facilities

We have been operating a 2,000L GMP-compliant bioreactor production line at our Beijing manufacturing plant during the Reporting Period, which mainly supports the production of clinical drug supply and offers CDMO production services. During the Reporting Period, we have recognized RMB6.3 million in revenue from the provision of CDMO services.

In addition, the construction of the Shanghai Biotech Park has been completed. The research and development center in the Shanghai Biotech Park has been put in use, which further enhances our capability to conduct pre-clinical, quality control and CMC research activities. The manufacturing facilities in the Shanghai Biotech Park have a designed total capacity of 12,000L, and has obtained the environmental impact assessment report for the production of mAb and ADC. Going forward, we will continue to build or expand our manufacturing facilities based on our business needs arising from the commercialization of our ADC candidates.

KEY EVENTS AFTER THE REPORTING PERIOD

Placing of new Shares under general mandate

References are made to the announcements of the Company dated July 4, 2025, and July 11, 2025, respectively. The Company placed 93,825,000 Shares to certain placees through placing agents at the placing price of HK\$5.02 per Share. Completion of the placing took place on July 11, 2025.

After deducting all applicable costs and expenses, including placing commission, legal fees and levies, the net proceeds raised amounted to approximately HK\$462.94 million. The net proceeds from the placing will be used as to (i) approximately 20% (being HK\$92.59 million) for the commercialization and marketing of the Company's core product MRG003 (EGFR-ADC); (ii) approximately 60% (being HK\$277.76 million) for advancing clinical trials of core products of the Company; and (iii) approximately 20% (being HK\$92.59 million) for the research and development of new product pipelines.

Completion of the H Share Full Circulation

On July 21, 2025, the conversion of 54,268,364 unlisted shares of the Company into H shares of the Company was completed, and listing of such converted H Shares commenced at 9:00 a.m. on July 22, 2025 on the Stock Exchange. Please refer to the Company's announcement dated July 21, 2025 for further details.

Licensing transaction

Reference is made to the announcement of the Company dated August 1, 2025. On August 1, 2025, the Company (as licensor and transferor) entered into a licensing transaction for the license-out and/or transfer of certain intellectual property rights relating to two pre-clinical assets developed by the Group's proprietary T cell engager-TOPAbody platform with Excalipoint (as licensees and transferees) through entering into the Intellectual Property Assignment and License Agreement and the Share Purchase Agreement.

MANAGEMENT DISCUSSION AND ANALYSIS

Pursuant to the Intellectual Property Assignment and License Agreement and the Share Purchase Agreement, and subject to the terms and conditions thereof, Excalipoint will obtain the exclusive rights to develop and commercialize the Target Products worldwide, in consideration for which the Company shall receive (i) an upfront payment in cash of US\$10 million in aggregate and, through Innocube (a wholly-owned subsidiary of the Company), ordinary shares to be issued by Excalipoint Cayman representing 10% of the enlarged issue capital of Excalipoint Cayman, (ii) development and commercial milestone payments in cash of up to US\$847.5 million in aggregate, and (iii) sales royalties at a tiered rate from low single-digit percentage to a mid single-digit percentage. In addition, the Group is entitled to appoint one director to the board of directors of Excalipoint Cayman.

MRG004A was granted BTB

In August 2025, MRG004A was granted BTB by the CDE, which offers a brand-new treatment option to patients with pancreatic cancer.

FUTURE DEVELOPMENT

The Company is an innovation-driven biopharmaceutical company focusing on oncology therapeutics, dedicated to promoting the technological advancement of innovative ADCs in China to better serve the unmet medical needs of cancer patients. Looking forward, we plan to leverage our competitive advantages through the following development strategies:

In respect of drug R&D, we strive to enrich our differentiated marketed product portfolio targeting indications with significant medical needs by combining our independent R&D capability with strategic collaborations. We will further focus on advancing strategic research and development priorities in next generation ADC drugs and IO bi/tri specific antibodies, while accelerating the commercialization of late-stage products. For our registrational stage product MRG003, the relevant authority is currently proceeding with the clinical and pharmaceutical evaluation in an orderly manner. We will concentrate our resources and endeavour to expedite the approval process. Meanwhile, our other key drug candidates are entering pivotal clinical stages. Protocol communication for the pivotal clinical trial of MRG004A has been completed, and we have entered the Phase III clinical trial stage in August 2025. In addition, we are currently conducting protocol communication with the CDE regarding the domestic pivotal clinical trial of CG0070. We will also explore further potential clinical value of our other innovative drug candidates, such as MRG006A and MRG007. Concurrently, the potential efficacy of combination therapies within our pipeline is being continuously explored, with greater clinical benefits striving to be delivered to a broader patient population.

In terms of domestic commercialization, we have successfully commercialized PUYOUHENG (Pucotenlimab Injection) through our own sales channels, which further validates our sales strategy and business model. We will take further actions to enhance the market accessibility of PUYOUHENG (Pucotenlimab Injection), accelerating market penetration at all levels to further increase market share. By leveraging the expertise and industry connections of our commercialization team, we will seek to foster our brand's image and market knowledge of our product through various methods, such as marketing and academic activities. At the same time, we will commence the preparation process for the commercial launch of MRG003 and continue to expand our marketing and commercialization teams. We believe that the enhancement of our efforts in terms of market outreach will translate into better market access, increased market share and increases in the sales of our commercialized product and our brand in general, thereby laying a solid market and channel foundation for the future commercialization of our ADC product pipeline.

MANAGEMENT DISCUSSION AND ANALYSIS

On the international front, we will ramp up our efforts to expand into the global market. Our ADC platform has been endorsed by multinational companies, evidenced by the successful out-licensing of CMG901's global rights to AstraZeneca and MRG007's ex-Greater China rights to ArriVent. We expect our other ADC products to have more promising business development opportunities. Going forward, we will persist in expanding our international network and exploring new business development cooperation opportunities. We remain committed to seeking more strategic partners worldwide to develop our ADC products and other innovative candidates through partnerships, licensing agreements, or joint ventures.

FINANCIAL REVIEW

Revenue

For the six months ended June 30, 2025, we have achieved a significant growth in revenue, recoding approximately RMB465.9 million (for the six months ended June 30, 2024: RMB133.3 million), approximately 3.5 times of the amount in the first half of 2024, which consists of (i) RMB309.0 million primarily from the out-licensing of MRG007 (for the six months ended June 30, 2024: RMB20.7 million); (ii) RMB150.6 million from the sales of PUYOUHENG (Pucotenlimab Injection), representing a remarkable increase of 58.8% compared to the same period in 2024 (for the six months ended June 30, 2024: RMB94.8 million); and (iii) RMB6.3 million for the provision of CDMO services (for the six months ended June 30, 2024: RMB17.8 million).

Cost of Sales

For the six months ended June 30, 2025, the Group has recorded cost of sales of approximately RMB27.4 million (for six months ended June 30, 2024: approximately RMB21.0 million).

Selling and Marketing Expenses

For the six months ended June 30, 2025, the Group has recorded selling and marketing expenses of RMB97.9 million (for six months ended June 30, 2024: RMB43.8 million), which was in line with the growth in sales revenue of PUYOUHENG (Pucotenlimab Injection) and licensing income of BD activities during the Reporting Period.

Administrative Expenses

Our administrative expenses primarily consist of (i) employee benefit expenses relating to our administrative staff; (ii) depreciation and amortization expenses, primarily representing depreciation expenses for right-of-use assets and property, plant and equipment; and (iii) others, mainly representing utilities as well as traveling and transportation expenses.

Our administrative expenses increased from RMB30.8 million for the six months ended June 30, 2024 to RMB55.4 million for the six months ended June 30, 2025, primarily due to (i) an increase in depreciation and property taxes following the completion and operation of Shanghai Biotech Park in 2024 and (ii) an increase in professional fees and service fees.

MANAGEMENT DISCUSSION AND ANALYSIS

Research and Development Expenses

Our research and development expenses primarily consist of (i) clinical study related expenses; (ii) pre-clinical study costs; (iii) raw materials and consumables used in pre-clinical and clinical studies; (iv) employee benefit expenses (mainly including wages, salaries and bonuses and share-based payment expenses) relating to our research and development staff; (v) depreciation and amortization expenses for property, plant and equipment as well as amortization expenses for intangible assets such as intellectual properties; and (vi) other expenses. Our research and development expenses for the six months ended June 30, 2025 was RMB202.2 million (for six months ended June 30, 2024: RMB216.6 million).

The following table sets forth the components of our research and development expenses for the periods indicated.

	Six months ended 30 June			
	2025		2024	
	RMB'000	%	RMB'000	%
Clinical study related expenses	78,829	39.0	84,670	39.1
Pre-clinical study costs	20,111	9.9	12,564	5.8
Raw materials and consumables	30,143	14.9	25,439	11.7
Employee benefit expenses	39,434	19.5	49,533	22.9
Depreciation and amortization	28,882	14.3	38,061	17.6
Others	4,844	2.4	6,343	2.9
Total	202,243	100.0	216,610	100.0

- (i) Clinical study related expenses for the six months ended June 30, 2025 decreased by RMB5.8 million, mainly due to our continued focus on our core drug candidates and prudent cost control;
- (ii) Pre-clinical study costs increased by RMB7.5 million given the Group has been continuously developing new innovative drug candidates;
- (iii) Raw materials and consumables expenses increased by RMB4.7 million, mainly due to the increase in the consumption of raw materials for the CMC research of the Group's core ADC drug candidates at the NDA stage;
- (iv) Employee benefit expenses decreased by RMB10.1 million, mainly due to the ongoing adaptive adjustment to meet the demand of the Group;
- (v) Depreciation and amortization costs decreased by RMB9.2 million, primarily due to the completion of depreciation for certain production-related property, plant and equipment by the end of 2024; and
- (vi) Other expenses for the six months ended June 30, 2025 decreased by RMB1.5 million as compared to the six months ended June 30, 2024.

MANAGEMENT DISCUSSION AND ANALYSIS

Fair Value Changes on Financial Liabilities at Fair Value through Profit or Loss

We had fair value loss on financial liabilities at fair value through profit or loss of RMB0.1 million for the six months ended June 30, 2024 and fair value loss of RMB17.0 million for the six months ended June 30, 2025. Our financial liabilities at fair value through profit or loss represent the variable part of the consideration arisen from the acquisition of 40% equity interests of Taizhou Hanzhong from non-controlling interest, being a certain portion of future annual net sales revenue of relevant PD-1 products.

The following table sets forth a breakdown of our fair value changes on financial liabilities at fair value through profit or loss for the periods indicated.

	Six months ended 30 June	
	2025 RMB'000	2024 RMB'000
Fair value changes on financial liabilities at fair value through profit or loss	(16,957)	(124)

Finance income and Finance Costs

Our finance income primarily represents our bank interest income and foreign exchange gain. Our finance costs primarily consist of interest costs on lease liabilities and borrowings.

Our finance income increased from RMB2.6 million for the six months ended June 30, 2024 to RMB7.5 million for the six months ended June 30, 2025, mainly due to an increase in foreign currency exchange gain. Our finance costs increased from RMB8.5 million for the six months ended June 30, 2024 to RMB14.9 million for the six months ended June 30, 2025, due to the completion and operation of Shanghai Biotech Park in 2024, which resulted in its loan interest no longer being capitalized.

Income Tax Expenses

For the six months ended June 30, 2025, the Group's income tax expenses were nil (for the six months ended June 30, 2024: nil).

Profit for the Reporting Period

Based on the factors described above, the Group's profit was RMB29.3 million, recording a turnaround to profit from loss of RMB197.0 million for the six months ended June 30, 2024, primarily attributable to the significant increase in revenue generated from licensing activities and the sales revenue growth of PUYOUHENG (Pucotenlimab Injection).

MANAGEMENT DISCUSSION AND ANALYSIS

Liquidity and Financial Resources

Our primary use of cash is to fund our research and development activities and support our commercialization activities. For the six months ended June 30, 2025, our net cash flows from operating activities was RMB46.7 million, an increase of RMB161.8 million from RMB115.1 million of net cash flows used in operating activities for the six months ended June 30, 2024. As of June 30, 2025, we had cash and cash equivalent of RMB472.7 million, representing an increase of RMB71.4 million from RMB401.3 million as of December 31, 2024, as a result of our rapid growth in revenue.

The main sources of the Group's liquidity are: (i) our operating activities, including domestic commercialization by our sales team, and licensing collaboration with strategic partners worldwide; (ii) equity financing; and (iii) bank borrowings.

Our bank borrowings are divided into secured loans and unsecured loans. As of June 30, 2025, the Group's bank borrowings amounted to RMB877.1 million (December 31, 2024: RMB794.4 million), among which unsecured and unguaranteed bank borrowings amounted to RMB647.0 million (December 31, 2024: RMB534.1 million) in total with interest at fixed and floating interest rates, among which RMB566.6 million of such borrowing will be repayable within one year.

As of June 30, 2025, the Group's secured and unguaranteed bank borrowings amounted to RMB230.1 million (December 31, 2024: RMB260.3 million) in total which bear interest at floating interest rates. Such bank borrowings are repayable by instalments and will mature in September 2027 and secured by the Group's land use rights and property, plant and equipment.

As of June 30, 2025, we had utilized RMB998.5 million from our banking facilities and approximately RMB651.5 million remained unutilized under our banking facilities.

Gearing Ratio

The gearing ratio is calculated using the Group's liabilities divided by its assets. As of June 30, 2025, the Group's gearing ratio was 69.9% (December 31, 2024: 70.1%).

Significant Investments, Material Acquisitions and Disposal

The Group did not have any significant investments or material acquisitions or disposals of subsidiaries, associates and joint ventures for the six months ended June 30, 2025.

Capital Commitments

As of June 30, 2025, the Group had capital commitments for property, plant and equipment of RMB448.7 million (December 31, 2024: RMB456.8 million), reflecting the capital expenditure of our Group contracted at the end of the Reporting Period/year but not yet incurred.

Contingent Liabilities

As of June 30, 2025, the Group did not have any contingent liabilities.

MANAGEMENT DISCUSSION AND ANALYSIS

Charges on Group Assets

Save as disclosed in this report, as of June 30, 2025, the Group did not have any charges over its assets.

Foreign Exchange Exposure

Our financial statements are expressed in RMB, but certain of our subsidiaries in the PRC are exposed to foreign exchange risk arising from recognized financial assets and liabilities which are denominated in foreign currencies. We currently do not have a foreign currency hedging policy. However, our management manages foreign exchange risk by performing regular reviews and will consider hedging significant foreign currency exposure should the need arise.

Employees and Remuneration

As of June 30, 2025, the Group had a total of 546 employees. The total remuneration cost of the Group for the six months ended June 30, 2025 was RMB110.3 million, as compared to RMB92.9 million for the six months ended June 30, 2024, primarily due to an increase in the expansion of the sales team.

To maintain the quality, knowledge and skill levels of our workforce, the Group provides regular and specialized trainings tailored to the needs of our employees in different departments, including regular training sessions conducted by senior employees or third-party consultants covering various aspects of our business operations, for our employees to stay up to date with both industry developments and skills and technologies. The Group also organizes workshops from time to time to discuss specific topics.

We provide various incentives and benefits to our employees. We offer competitive remuneration packages to our employees to effectively motivate our business development team. We participate in various social security plans (including housing provident fund, pension insurance, medical insurance, maternity insurance and work-related injury insurance and unemployment insurance) for our employees in accordance with applicable PRC laws.

USE OF PROCEEDS FROM THE LISTING

On the Listing Date, the Company's shares were listed on the Stock Exchange, and on March 17, 2022, the over-allotment option granted as part of the Global Offering was partially exercised. The net proceeds received by the Group from the initial public offering of the Company (after deducting underwriting fee and relevant listing expenses and taking into account the net proceeds from the over-allotment option) amounted to approximately HK\$810.42 million (equivalent to approximately RMB657.61 million).

The net proceeds from the Listing (pro-rata adjustment based on the actual net proceeds) have been and will be used in accordance with the purposes set out in the Prospectus. The following table sets forth the planned use of the net proceeds and the actual use as at June 30, 2025:

MANAGEMENT DISCUSSION AND ANALYSIS

Proposed use	Percentage of total net proceeds	Allocation of net proceeds (RMB million)	Utilized amount as at June 30, 2025 (RMB million)	Utilized amount during the Reporting Period (RMB million)	Unutilized amount as at June 30, 2025 (RMB million)
a) To fund our Core Products	68.51%	450.57	439.50	26.43	11.07
• To be used for MRG003	23.00%	151.28	151.28	22.90	–
– To fund the clinical development and preparation for registration filings of MRG003	19.27%	126.75	126.75	22.82	–
– To fund the manufacturing of MRG003	3.73%	24.53	24.53	0.08	–
• To be used for MRG002	22.01%	144.74	144.74	–	–
– To fund the clinical development and preparation for registration filings of MRG002	18.65%	122.66	122.66	–	–
– To fund the manufacturing of MRG002	3.36%	22.08	22.08	–	–
• To be used for HX008	16.17%	106.30	106.30	–	–
– To fund the clinical development and preparation for registration filings of HX008	7.46%	49.06	49.06	–	–
– To fund the manufacturing of HX008	6.22%	40.89	40.89	–	–
– To fund the commercialization of HX008	2.49%	16.35	16.35	–	–
• To fund the clinical development and preparation for registration filings of LP002	1.24%	8.18	8.18	–	–
• To be used to fund the planned clinical development and other development activities of the combination therapies of HX008 and LP002 with our other products including MRG003, MRG002 and CG0070	6.09%	40.07	29.00	3.53	11.07

MANAGEMENT DISCUSSION AND ANALYSIS

Proposed use	Percentage of total net proceeds	Allocation of net proceeds (RMB million)	Utilized amount as at June 30, 2025 (RMB million)	Utilized amount during the Reporting Period (RMB million)	Unutilized amount as at June 30, 2025 (RMB million)
b) To fund our other key clinical-stage drug candidates and our key pre-clinical drug candidates	6.35%	41.70	40.35	1.10	1.35
• Ongoing pre-clinical studies and planned clinical trials for the pre-clinical drug candidates in our pipeline	0.62%	4.09	4.09	–	–
• To fund the clinical development and preparation for registration filings of CG0070	1.87%	12.27	11.72	1.10	0.55
• To fund the clinical development and preparation for registration filings of MRG001	1.87%	12.27	12.27	–	–
• To fund the clinical development and preparation for registration filings of MRG004A	1.87%	12.27	12.27	–	–
• To fund, through our contribution to KYM, the clinical development and preparation for registration filings of CMG901	0.12%	0.80	0.00	–	0.80
c) To acquire potential technologies and assets and expand our pipeline of drug candidates and to fulfill our continuous payment obligation under our acquisition of HX008 from HanX	15.79%	103.85	103.85	–	–
d) For general corporate purposes	9.35%	61.49	61.49	–	–
Total	100%	657.61	645.19	27.53	12.42

The licensing income from BD activities and the commercialization of PUYOUHENG (Pucotenlimab Injection) had generated revenue and additional cashflow for the Group, therefore the usage of the net proceeds from the Listing has been extended. The unutilized amount of net proceeds from the Listing is expected to be used by December 31, 2025.

MANAGEMENT DISCUSSION AND ANALYSIS

USE OF PROCEEDS FROM THE 2024 PLACING

References are made to the announcements of the Company dated May 17, 2024 and May 24, 2024, respectively.

The Company placed 51,170,000 H Shares in aggregate at the price of HK\$4.58 per Share under a general mandate approved at the 2022 annual general meeting (the “**2024 Placing**”) to not less than six placees who were professional, institutional and/or other investors. The closing price was HK\$4.95 per H Share as quoted on the Stock Exchange on the date of the placing agreement. Completion of the Placing took place on May 24, 2024. Based on the nominal value of RMB1.00 per H Share, the aggregate nominal value of the Placing Shares is RMB51,570,000. The Directors considered that the Placing would strengthen the liquidity and financial position of the Group, and that the Placing was undertaken to further enlarge the Shareholders’ equity base of the Company, optimize the capital structure of the Company, and support the healthy and sustainable development of the Company. For further details, please refer to the announcements of the Company dated May 17, 2024 and May 24, 2024.

After deducting all applicable costs and expenses, including placing commission, legal fees and levies, the net proceeds raised amounted to approximately HK\$229.75 million (equivalent to approximately RMB209.18 million). The table below sets out the actual usage up to June 30, 2025:

Proposed use	Percentage of total net proceeds (Approximately)	Allocation of net proceeds (RMB million)	Utilized amount as at June 30, 2025 (RMB million)	Utilized amount during the Reporting Period (RMB million)	Unutilized amount as at June 30, 2025 (RMB million)
i) To be used for the R&D, clinical trials, registration filings and other workstreams of the Company’s ADC product candidates	70.00%	146.43	84.43	59.85	62.00
ii) To be used for the clinical trials and other workstreams of CG0070	20.00%	41.84	0.14	0.14	41.70
iii) To replenish the Company’s working capital and for general corporate purposes	10.00%	20.92	19.87	0	1.05
Total	100%	209.18	104.44	59.99	104.75

The unutilized amount of net proceeds from the Placing is expected to be used by December 31, 2026.

OTHER INFORMATION

INTERESTS AND SHORT POSITIONS OF DIRECTORS, SUPERVISORS AND CHIEF EXECUTIVE IN SHARES, UNDERLYING SHARES AND DEBENTURES OF THE COMPANY AND ITS ASSOCIATED CORPORATIONS

As at June 30, 2025, the interests and short positions of the Directors, Supervisors, and the chief executives of the Company in the Shares, underlying Shares and debentures of the Company or its associated corporation (within the meaning of Part XV of the SFO) which were required to be entered in the register kept by the Company pursuant to section 352 of the SFO, or which were otherwise required, to be notified to the Company and the Stock Exchange pursuant to the Model Code, are set out below:

Interests of our Directors in the Shares or Underlying Shares of the Company

Long position in the Shares as at June 30, 2025

Name of Director	Class of Shares	Nature of Interest	Number of Shares or underlying Shares	Approximate percentage in relevant class of Shares ⁽¹⁾	Approximate percentage of shareholding ⁽¹⁾
Dr. Pu Zhongjie ⁽²⁾	H Shares	Interests in controlled corporation	658,591,549	39.76%	38.50%
Ms. Pu Jue ⁽³⁾	H Shares	Interests in controlled corporation	90,000,000	5.43%	5.26%

Notes:

- (1) The calculation is based on the total number of 1,710,614,838 issued, including 1,656,346,474 H Shares and 54,268,364 Domestic Shares issued as at June 30, 2025.
- (2) Ningbo Houde Yimin directly holds 433,239,436 H Shares as beneficial owner, and Ningbo Houde Yimin is held as to 100% by Beijing Houde Yimin, which is in turn held as to 100% by Dr. Pu Zhongjie, an executive Director and the chairman of the Board. In addition, Lepu Medical directly holds 225,352,113 H Shares as beneficial owner, and Dr. Pu Zhongjie is the actual controller of Lepu Medical. Dr. Pu Zhongjie is therefore deemed to be interested in the 433,239,436 H Shares and the 225,352,113 H Shares held by Ningbo Houde Yimin and Lepu Medical, respectively.
- (3) Shanghai Lvyuan directly holds 90,000,000 H Shares as beneficial owner, and Shanghai Lvyuan is held as to 100% by Cereblue Limited, which is in turn held as to 100% by Ms. Pu Jue, a non-executive Director. Ms. Pu Jue is therefore deemed to be interested in the 90,000,000 H Shares held by Shanghai Lvyuan.

Interests of our Directors in the Shares or Underlying Shares of Associated Corporations

So far as the Directors are aware, as at June 30, 2025, none of the Directors, Supervisors, or chief executives of the Company had any interests and/or short positions in the Shares, underlying Shares and debentures of the Company's associated corporations, which were required to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests and short positions which he is taken or deemed to have under such provisions of SFO), or were required to be recorded in the register required to be kept under section 352 of the SFO or required to be notified to the Company and the Stock Exchange pursuant to the Model Code.

OTHER INFORMATION

INTERESTS AND SHORT POSITIONS OF SUBSTANTIAL SHAREHOLDERS IN SHARES AND UNDERLYING SHARES OF THE COMPANY

So far as is known to the Company, as at June 30, 2025, as recorded in the register required to be kept by the Company under section 336 of the SFO, the following persons, other than a Director or chief executive of the Company, had an interest of 5% or more in the Shares or underlying Shares:

Long position in the Shares as at June 30, 2025

Name of Shareholder	Class of Shares	Nature of Interest	Number of Shares or underlying Shares	Approximate percentage in relevant class of Shares ⁽¹⁾	Approximate percentage of shareholding ⁽¹⁾
Miracogen HK	H Shares	Beneficial interest	131,496,106	7.94%	7.69%
Miracogen Inc. ⁽²⁾	H Shares	Interest in controlled corporation	131,496,106	7.94%	7.69%
Dr. Hu Chaohong ⁽²⁾	H Shares	Interest in controlled corporation	131,496,106	7.94%	7.69%
Kington Capital No. 1 Equity Investment Partnership (Limited Partnership)* 蘇州翼樸一號股權投資合夥企業(有限合夥) ("Kington Capital")	H Shares	Beneficial interest	39,436,621	2.38%	2.31%
	Domestic Shares	Beneficial interest	39,436,620	72.67%	2.31%
Suzhou Yipu No. 1 Chuangzhe Management Consultation Limited Partnership* 蘇州翼樸一號創喆管理諮詢合夥企業(有限合夥) ("Suzhou Yipu No.1") ⁽³⁾	H Shares	Interest in controlled corporation	39,436,621	2.38%	2.31%
	Domestic Shares	Interest in controlled corporation	39,436,620	72.67%	2.31%
Suzhou Suzi Investment Limited Partnership* 蘇州蘇梓投資合夥企業(有限合夥) ("Suzhou Suzi")	Domestic Shares	Beneficial interest	9,859,155	18.17%	0.58%
Suzhou Zisu Investment Consultation Limited Partnership* 蘇州梓蘇投資諮詢合夥企業(有限合夥) ("Suzhou Zisu") ⁽⁴⁾	Domestic Shares	Interest in controlled corporation	9,859,155	18.17%	0.58%
Shanghai Qianyu Equity Investment Fund Management Co., Ltd.* 上海前宇股權投資基金管理有限公司 ("Shanghai Qianyu") ⁽⁴⁾	Domestic Shares	Interest in controlled corporation	9,859,155	18.17%	0.58%

OTHER INFORMATION

Name of Shareholder	Class of Shares	Nature of Interest	Number of Shares or underlying Shares	Approximate percentage in relevant class of Shares ⁽¹⁾	Approximate percentage of shareholding ⁽¹⁾
Suzhou Yumeng Investment Management Co., Ltd.* 蘇州宇夢投資管理有限公司 (“Suzhou Yumeng”) ⁽⁴⁾	Domestic Shares	Interest in controlled corporation	9,859,155	18.17%	0.58%
Qian Xin (US) (錢鑫) ⁽⁴⁾	Domestic Shares	Interest in controlled corporation	9,859,155	18.17%	0.58%
Yinhua Changan Capital Management (Beijing) Co., Ltd.* 銀華長安資本管理(北京)有限公司 (“Yinhua Changan”) ⁽⁴⁾	Domestic Shares	Interest in controlled corporation	9,859,155	18.17%	0.58%
Yinhua Fund Management Co., Ltd.* 銀華基金管理股份有限公司 (“Yinhua Fund”) ⁽⁴⁾	Domestic Shares	Interest in controlled corporation	9,859,155	18.17%	0.58%
Southwest Securities Co., Ltd. (西南證券有限責任公司) (“Southwest Securities”) ⁽⁴⁾	Domestic Shares	Interest in controlled corporation	9,859,155	18.17%	0.58%
Suzhou Kington Equity Investment Fund Management Co., Ltd. (蘇州翼模股權投資基金管理有限公司) (“Suzhou Kington”) ⁽⁵⁾	H Shares	Interest in controlled corporation	39,436,621	2.38%	2.31%
	Domestic Shares	Interest in controlled corporation	49,295,775	90.84%	2.88%
Suzhou Private Capital Investment Holdings Co., Ltd. (蘇州民營資本投資控股有限公司) (“Suzhou Private Capital Investment”) ⁽⁶⁾	H Shares	Interest in controlled corporation	39,436,621	2.38%	2.31%
	Domestic Shares	Interest in controlled corporation	49,295,775	90.84%	2.88%
Shanghai Healthcare Capital Partnership (Limited Partnership) (上海生物醫藥產業股權投資基金合夥企業(有限合夥)) (“SHC”)	H Shares	Beneficial interest	10,962,335	0.66%	0.64%
	Domestic Shares	Beneficial interest	3,654,111	6.73%	0.21%
Shanghai Healthcare Capital Investment Fund Co., Ltd. (上海生物醫藥產業股權投資基金管理有限公司) (“Shanghai Healthcare”) ⁽⁷⁾	H Shares	Interest in controlled corporation	10,962,335	0.66%	0.64%
	Domestic Shares	Interest in controlled corporation	3,654,111	6.73%	0.21%

OTHER INFORMATION

Notes:

- (1) The calculation is based on the total number of 1,710,614,838 Shares issued, including 1,656,346,474 H Shares and 54,268,364 Domestic Shares issued as at June 30, 2025.
- (2) Miracogen HK directly holds 131,496,106 H Shares as beneficial owner, and Miracogen HK is held as to 100% by Miracogen Inc., which is in turn held as to 100% by Dr. Hu Chaohong. Dr. Hu Chaohong and Miracogen Inc. are therefore deemed to be interested in the 131,496,106 H Shares held by Miracogen HK.
- (3) Suzhou Yipu No. 1 is the general manager of Kington Capital and therefore is deemed to be interested in our Shares held by Kington Capital.
- (4) Suzhou Zisu is the general partner of Suzhou Suzi, with Suzhou Kington being its general partner and Shanghai Qianyu being its limited partners holding 50% partnership interest. Suzhou Kington is wholly owned by Suzhou Private Capital Investment and Shanghai Qianyu is owned as to 60% by Suzhou Yumeng, a company owned by Qian Xin as to 99.50%.

Yinhua Changan is the limited partner of Suzhou Suzi holding 69.47% partnership interest, which in turn is wholly owned by Yinhua Fund and Southwest Securities owns 44.1% equity interest in Yinhua Fund.

Therefore, each of Suzhou Zisu, Suzhou Kington, Shanghai Qianyu, Suzhou Yumeng, Qian Xin, Yinhua Changan, Yinhua Fund and Southwest Securities is deemed to be interested in our Shares held by Suzhou Suzi.
- (5) Suzhou Kington is the general partner of Suzhou Yipu No. 1 and Suzhou Zisu, and therefore deemed to be interested in our Shares held by Kington Capital and Suzhou Suzi.
- (6) Suzhou Private Capital Investment holds 100% equity interest in Suzhou Kington and is therefore deemed to be interested in our Shares held by Kington Capital and Suzhou Suzi.
- (7) Shanghai Healthcare is the general partner of SHC and therefore is deemed to be interested in our Shares held by SHC.

Save as disclosed above, as at June 30, 2025, the Company had not been notified of any persons (other than a Director or chief executive of the Company) who had an interest or short position in the Shares or underlying Shares that were recorded in the register required to be kept under section 336 of the SFO.

ARRANGEMENTS TO PURCHASE SHARES OR DEBENTURES

At no time during the Reporting Period was the Company or any of its subsidiaries a party to any arrangements to enable the Directors to acquire benefits by means of the acquisition of shares in, or debentures of, the Company or any other body corporate; and none of the Directors, or any of their spouse or children under the age of 18, had any right to subscribe for equity or debt securities of the Company or any other body corporate, or had exercised any such right.

PURCHASE, SALE AND REDEMPTION OF LISTED SECURITIES OF THE COMPANY

Neither the Company nor any of its subsidiaries has made any purchase, sale or redemption of the listed securities of the Company (including sale of treasury shares) during the Reporting Period.

As at 30 June 2025, the Company did not hold any treasury shares.

OTHER INFORMATION

SHARE SCHEME

During the Reporting Period and up to the Latest Practicable Date, the Company did not adopt any share scheme under Chapter 17 of the Listing Rules.

COMPLIANCE WITH THE CORPORATE GOVERNANCE CODE

The Company has adopted the principles and code provisions as set out in the Corporate Governance Code and has complied with all applicable code provisions during the six months ended June 30, 2025.

CHANGES IN DIRECTORS' AND SUPERVISORS' INFORMATION

As disclosed in the announcement of the Company dated June 6, 2025, Mr. Yang Hongbing has resigned from his position as a non-executive Director of the Company due to pursuit of other professional and personal engagements. The Board proposed to appoint Ms. Qin Yiran ("**Ms. Qin**") as a non-executive Director. Her term of office commenced from June 27, 2025, the date on which the relevant resolution was passed at the 2024 Annual General Meeting of the Company ("**2024 AGM**"), until the expiration of the term of the second session of the Board, subject to re-election upon the expiry of her term of office.

Details of the biography of Ms. Qin can be found in the announcement of the Company dated June 6, 2025, and the Circular of the 2024 AGM dated June 6, 2025.

Save as disclosed above, there are no material changes in Directors, Supervisors and senior management of the Company and their respective biographies from the date of the 2024 annual report up to the Latest Practicable Date that need to be disclosed pursuant to Rule 13.51B(1) of the Listing Rules.

MODEL CODE FOR SECURITIES TRANSACTIONS

The Company has adopted the Model Code as its own code of conduct regarding securities transactions by the Directors and Supervisors. Having made specific enquiries with all Directors and Supervisors, each of them has confirmed that he/she has complied with the Model Code for the six months ended June 30, 2025. No incident of non-compliance of the Model Code by the employees who are likely to be in possession of inside information of the Company was noted by the Company.

OTHER INFORMATION

REVIEW OF INTERIM REPORT

The independent auditor of the Company, namely, Ernst & Young, has carried out a review of the interim financial information in accordance with the International Standard on Review Engagements 2410, “Review of Interim Financial Information Performed by the Independent Auditor of the Entity” issued by the International Auditing and Assurance Standards Board. The Audit Committee has jointly reviewed with the management and the independent auditor of the Company the accounting principles and policies adopted by the Group and the Group’s financial reporting matters (including the review of the unaudited interim condensed consolidated financial statements for the six months ended June 30, 2025 and this interim report). The Audit Committee considered that the interim results are in compliance with the applicable accounting standards, laws and regulations, and the Company has made appropriate disclosures thereof.

INTERIM DIVIDEND

The Board does not recommend the payment of an interim dividend for the six months ended June 30, 2025 (June 30, 2024: nil).

By order of the Board of

Lepu Biopharma Co., Ltd.

Dr. Pu Zhongjie

Chairman and Executive Director

Shanghai, the PRC

September 19, 2025

REPORT ON REVIEW OF INTERIM FINANCIAL INFORMATION

To the Board of Directors of Lepu Biopharma Co., Ltd.

(incorporated in the People's Republic of China with limited liability)

INTRODUCTION

We have reviewed the interim financial information set out on pages 30 to 54, which comprises the condensed consolidated statement of financial position of Lepu Biopharma Co., Ltd. (the “**Company**”) and its subsidiaries (the “**Group**”) as at 30 June 2025 and the related condensed consolidated statement of profit or loss and other comprehensive income, changes in equity and cash flows for the six-month period then ended, and explanatory notes. The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited require the preparation of a report on interim financial information to be in compliance with the relevant provisions thereof and International Accounting Standard 34 Interim Financial Reporting (“**IAS 34**”) as issued by the International Accounting Standards Board. The directors of the Company are responsible for the preparation and presentation of this interim financial information in accordance with IAS 34. Our responsibility is to express a conclusion on this interim financial information based on our review. Our report is made solely to you, as a body, in accordance with our agreed terms of engagement, and for no other purpose. We do not assume responsibility towards or accept liability to any other person for the contents of this report.

SCOPE OF REVIEW

We conducted our review in accordance with International Standard on Review Engagements 2410 *Review of Interim Financial Information Performed by the Independent Auditor of the Entity* as issued by the International Auditing and Assurance Standards Board. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

CONCLUSION

Based on our review, nothing has come to our attention that causes us to believe that the interim financial information is not prepared, in all material respects, in accordance with IAS 34.

Ernst & Young

Certified Public Accountants

Hong Kong

20 August 2025

INTERIM CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

For the six months ended 30 June 2025

	Notes	2025 RMB'000 (Unaudited)	2024 RMB'000 (Unaudited)
REVENUE	7	465,942	133,283
Cost of sales	9	(27,403)	(21,042)
Gross profit		438,539	112,241
Other income	8	1,964	651
Selling and marketing expenses		(97,879)	(43,789)
Administrative expenses		(55,376)	(30,844)
Research and development expenses		(202,243)	(216,610)
Fair value changes on financial liabilities at fair value through profit or loss ("FVTPL")		(16,957)	(124)
Other losses, net	10	(25,067)	(5,561)
Operating income/(loss)		42,981	(184,036)
Finance income		7,482	2,572
Finance costs		(14,927)	(8,465)
Finance costs, net	11	(7,445)	(5,893)
Share of loss of investments accounted for using the equity method	17	(6,234)	(7,037)
Profit/(loss) before income tax		29,302	(196,966)
Income tax expense	12	–	–
Profit/(loss) for the period		29,302	(196,966)
Profit/(loss) attributable to:			
Owners of the Company		41,745	(192,430)
Non-controlling interests		(12,443)	(4,536)
		29,302	(196,966)
Other comprehensive income/(loss)			
<i>Items that may be subsequently reclassified to profit or loss</i>			
Currency translation differences		104	85
Share of other comprehensive income of associates		(6)	–
Total comprehensive income/(loss)		29,400	(196,881)
Total comprehensive income/(loss) attributable to:			
Owners of the Company		41,843	(192,345)
Non-controlling interests		(12,443)	(4,536)
		29,400	(196,881)
Earnings/(loss) per share for loss attributable to owners of the Company for the period (expressed in RMB per share)			
– Basic	13	0.02	(0.12)
– Diluted	13	0.02	(0.12)

INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

30 June 2025

		As at 30 June 2025 RMB'000 (Unaudited)	As at 31 December 2024 RMB'000 (Audited)
	Notes		
Assets			
Non-current assets			
Property, plant and equipment	14	941,514	930,106
Right-of-use assets	15	110,608	120,932
Intangible assets	16	462,565	435,250
Investments accounted for using the equity method	17	108,425	114,073
Other receivables, prepayments and deposits	18	34,041	34,816
Total non-current assets		1,657,153	1,635,177
Current assets			
Inventories		46,812	22,787
Trade receivables	19	49,749	45,821
Other receivables, prepayments and deposits	18	71,556	111,986
Financial assets at FVTPL	20	63,628	63,628
Cash and cash equivalents		472,708	401,286
Total current assets		704,453	645,508
Total assets		2,361,606	2,280,685
Equity			
Equity attributable to owners of the Company			
Share capital	21	1,710,615	1,710,615
Reserves		1,757,862	1,757,172
Accumulated losses		(2,723,217)	(2,764,962)
		745,260	702,825
Non-controlling interests		(33,465)	(21,022)
Total equity		711,795	681,803

INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

		As at 30 June 2025 RMB'000 (Unaudited)	As at 31 December 2024 RMB'000 (Audited)
	Notes		
Liabilities			
Non-current liabilities			
Borrowings	22	240,337	255,940
Lease liabilities		3,847	11,455
Deferred government grants		17,840	18,020
Deferred tax liabilities	23	37,687	37,687
Financial liabilities at FVTPL	24	238,304	232,267
Total non-current liabilities		538,015	555,369
Current liabilities			
Borrowings	22	636,787	538,411
Trade payables	25	226,205	236,135
Other payables and accruals		211,271	233,684
Lease liabilities		36,835	34,378
Contract liabilities		698	905
Total current liabilities		1,111,796	1,043,513
Total liabilities		1,649,811	1,598,882
Total equity and liabilities		2,361,606	2,280,685

The above condensed consolidated balance sheet should be read in conjunction with the accompanying notes.

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

For the six months ended 30 June 2025

	Note	Attributable to owners of the Company			Non-controlling interests	Total
		Share capital	Reserves	Accumulated losses		
		RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
At 1 January 2024		1,659,445	1,591,046	(2,353,586)	(8,205)	888,700
Comprehensive loss						
Loss for the period		–	–	(192,430)	(4,536)	(196,966)
Other comprehensive income		–	85	–	–	85
Issuance of shares	21	51,170	157,821	–	–	208,991
Share-based payments		–	(1,804)	–	–	(1,804)
Other		–	3,004	–	–	3,004
At 30 June 2024 (Unaudited)		1,710,615	1,750,152	(2,546,016)	(12,741)	902,010
At 1 January 2025		1,710,615	1,757,172	(2,764,962)	(21,022)	681,803
Comprehensive income						
Profit/(loss) for the period		–	–	41,745	(12,443)	29,302
Other comprehensive income		–	98	–	–	98
Other		–	592	–	–	592
At 30 June 2025 (Unaudited)		1,710,615	1,757,862	(2,723,217)	(33,465)	711,795

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

For the six months ended 30 June 2025

	2025 RMB'000 (Unaudited)	2024 RMB'000 (Unaudited)
Cash flows from operating activities		
Profit/(loss) before tax	29,302	(196,966)
Total non-cash adjustments	77,100	57,615
Total working capital adjustments	(62,649)	22,078
Cash generated from/(used in) operations	43,753	(117,273)
Interest received	2,943	2,143
Net cash generated from/(used in) operating activities	46,696	(115,130)
Cash flows from investing activities		
Proceeds from disposal of property, plant and equipment	3,968	–
Payments for property, plant and equipment	(32,089)	(12,157)
Payments for financial assets at FVTPL	(35,000)	–
Proceeds from disposal of financial assets at FVTPL	35,055	–
Payments for intangible assets	(25,213)	(11,462)
Refund of deposits for land use rights	10,113	–
Net cash used in investing activities	(43,166)	(23,619)
Cash flows from financing activities		
Proceeds from issuance of shares	–	213,379
Payments for share issuance costs	–	(3,441)
Proceeds from bank borrowings	368,980	295,542
Repayments of bank borrowings	(286,130)	(260,214)
Payments of lease liabilities		
– Principal	(5,151)	(5,264)
– Interest	(442)	(183)
Bank loan interest paid	(13,904)	(13,834)
Net cash generated from financing activities	63,353	225,985
Net increase in cash and cash equivalents	66,883	87,236
Cash and cash equivalents at the beginning of period	401,286	426,015
Effects of exchange rate changes on cash and cash equivalents	4,539	389
Cash and cash equivalents at end of period	472,708	513,640
ANALYSIS OF BALANCES OF CASH AND CASH EQUIVALENTS		
Cash and bank balances as stated in the statement of financial position	472,708	513,640
Cash and cash equivalents as stated in the statement of cash flows	472,708	513,640

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

1. GENERAL INFORMATION

Lepu Biopharma Co., Ltd. (the “**Company**”) was incorporated in Shanghai, the People’s Republic of China (the “**PRC**”) on 19 January 2018 as a limited liability company. Upon approval by the shareholders’ general meeting held on 10 December 2020, the Company was converted into a joint stock company with limited liability under the Company Law of the PRC.

The Company, together with its subsidiaries (collectively referred to as the “**Group**”), are principally focused on the discovery, development and commercialisation of drugs for cancer-targeted therapy and immunotherapy globally.

This interim condensed consolidated financial information is presented in Renminbi (“**RMB**”) and all values are rounded to the nearest thousand unless otherwise stated.

This unaudited interim condensed consolidated financial information was approved for issue by the board of directors of the Company on 20 August 2025.

2. BASIS OF PREPARATION

The Group’s interim condensed consolidated financial information for the six months ended 30 June 2025 has been prepared in accordance with IAS 34 Interim Financial Reporting.

The interim condensed consolidated financial information does not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group’s annual consolidated financial statements for the year ended 31 December 2024.

As at 30 June 2025, the Group had net current liabilities of approximately RMB407 million and cash and cash equivalents of approximately RMB473 million. Historically, the Group has relied principally on non-operational sources of financing from investors and banks as well as cash generated from sales activities to fund its operations and business development. The Group’s ability to continue as a going concern is dependent on management’s ability to successfully execute its business plan. The directors of the Company believes that the cash and cash equivalent, unutilised bank facilities together with the cash generated from operating activities are sufficient to meet the cash requirements to fund planned operations and other commitments for at least the next twelve months from 30 June 2025. The Group therefore continues to prepare this interim condensed consolidated financial information on a going concern basis.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

3. CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES

The accounting policies adopted in the preparation of the interim condensed consolidated financial information are consistent with those applied in the preparation of the Group's annual consolidated financial statements for the year ended 31 December 2024, except for the adoption of the following amended IFRS Accounting Standard for the first time for the current period's financial information.

Amendments to IAS 21

Lack of Exchangeability

The nature and impact of the amended IFRS Accounting Standard are described below:

Amendments to IAS 21 specify how an entity shall assess whether a currency is exchangeable into another currency and how it shall estimate a spot exchange rate at a measurement date when exchangeability is lacking. The amendments require disclosures of information that enable users of financial statements to understand the impact of a currency not being exchangeable. As the currencies that the Group had transacted with and the functional currencies of group entities for translation into the Group's presentation currency were exchangeable, the amendments did not have any impact on the interim condensed consolidated financial information.

4. ESTIMATES

The preparation of interim condensed consolidated financial information requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets and liabilities, income and expense. Actual results may differ from these estimates.

In preparing this interim condensed consolidated financial information, the significant judgments made by management in applying the Group's accounting policies and the key sources of estimation uncertainty were the same as those that applied to the 2024 Annual Financial Statements.

5. FINANCIAL RISK MANAGEMENT

5.1 Financial risk factors

The Group's activities expose it to a variety of financial risks: market risk, credit risk and liquidity risk.

The interim condensed consolidated financial information does not include all financial risk management information and disclosures required in the annual financial statements, and should be read in conjunction with the 2024 Annual Financial Statements.

There have been no significant changes in the risk management policies since 31 December 2024.

5.2 Liquidity risk

There was no material change in the contractual undiscounted cash outflows for financial liabilities.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

5. FINANCIAL RISK MANAGEMENT (CONTINUED)

5.3 Fair value estimation

Financial assets at FVTPL of the Group represents an equity investment in private company.

Financial liabilities at FVTPL represents the variable consideration payable arisen from acquisition of 40% equity interests of certain subsidiary from non-controlling interest.

The following table presents the Group's assets and liabilities that were measured at fair value as at 30 June 2025 and 31 December 2024.

	Level 1 RMB'000	Level 2 RMB'000	Level 3 RMB'000	Total RMB'000
At 30 June 2025 (Unaudited)				
Financial assets				
Financial assets at FVTPL (Note 20)	–	–	63,628	63,628
Financial liabilities				
Financial liabilities at FVTPL (Note 24)	–	–	280,069	280,069
At 31 December 2024 (Audited)				
Financial assets				
Financial assets at FVTPL (Note 20)	–	–	63,628	63,628
Financial liabilities				
Financial liabilities at FVTPL (Note 24)	–	–	263,112	263,112

- (a) There were no changes in Level 3 of financial assets at FVTPL for the six months ended 30 June 2025 and 2024.
- (b) The changes of financial liabilities at FVTPL for the six months ended 30 June 2025 and 2024 are presented in Note 24.

6. SEGMENT INFORMATION

Management has determined that the operating segments is based on the reports reviewed by the chief operating decision-maker ("CODM"). The CODM, who is responsible for allocating resources and assessing performance of the operating segment, has been identified as the executive directors of the Group.

During the reporting period, the Group has been principally engaged in the sales of pharmaceutical products and research and development of new drugs. Management reviews the operating results of the business as one operating segment to make decisions about resources to be allocated. Therefore, the CODM of the Company regards that there is only one segment which is used to make strategic decisions.

The major operating entity of the Group is domiciled in Mainland China. Accordingly, the Group's results were primarily derived in Mainland China during the reporting period, and its non-current assets were also primarily located in Mainland China.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

7. REVENUE

	Six months ended 30 June	
	2025 RMB'000 (Unaudited)	2024 RMB'000 (Unaudited)
Revenue recognised at a point in time		
– Sales of pharmaceutical products	150,645	94,836
– Licensing income	309,039	20,678
	459,684	115,514
Revenue recognised over time		
– CDMO services	6,258	17,769
Total	465,942	133,283

Information about the geographical markets of the Group's revenue is presented based on the locations of the customers.

	Six months ended 30 June	
	2025 RMB'000 (Unaudited)	2024 RMB'000 (Unaudited)
Geographical markets		
– Mainland China	156,903	112,605
– Overseas	309,039	20,678
Total	465,942	133,283

For the six months ended 30 June 2025, revenue of approximately RMB295,033,000 was derived from licensing income from ArriVent BioPharma INC., which accounted for 63.32% of the Group's total revenue.

For the six months ended 30 June 2024, revenue of approximately RMB20,678,000 was derived from licensing income from one of the Group's associates, KYM Biosciences Inc. ("KYM"), which accounted for 15.51% of the Group's total revenue, and revenue of approximately RMB16,181,000 was derived from CDMO services income from one of the Group's related parties (Note 27), Beijing Lepu Pharmaceutical Technology Co., Ltd. ("Beijing Lepu Pharmaceutical"), which accounted for 12.14% of the Group's total revenue.

Other than the aforementioned customers, the revenues derived from any of the remaining external customers were less than 10% of the Group's total revenue.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

8. OTHER INCOME

	Six months ended 30 June	
	2025 RMB'000 (Unaudited)	2024 RMB'000 (Unaudited)
Government grants	1,032	202
Individual income tax refund	225	316
Investment income from financial assets at FVTPL	55	–
Others	652	133
Total	1,964	651

9. PROFIT BEFORE TAX

	Notes	Six months ended 30 June	
		2025 RMB'000 (Unaudited)	2024 RMB'000 (Unaudited)
Cost of sales		27,403	21,042
Depreciation of property, plant and equipment	14	24,819	23,354
Depreciation of right-of-use assets	15	6,984	8,573
Amortisation of other intangible assets	16	15,383	15,208
Research and development costs (excluding depreciation, amortisation and employee benefit expenses)		133,927	129,016
Lease payments not included in the measurement of lease liabilities		371	312
Auditor's remuneration		943	1,000
Employee benefit expenses:			
Wages, salaries and welfare		87,626	72,896
Share-based payment expenses		–	(1,804)
Pension scheme contributions		9,780	8,521
Other social security costs, housing benefits and other employee benefits		12,916	13,330
Less: Amount capitalised		(8,497)	–
Foreign exchange differences, net	11	4,539	429

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

10. OTHER LOSSES, NET

	Six months ended 30 June	
	2025 RMB'000 (Unaudited)	2024 RMB'000 (Unaudited)
Donation	25,783	5,738
Expected credit losses	16	(166)
Net gains on disposal of property, plant and equipment	(891)	–
Net gains on disposal of right-of-use assets	–	(11)
Others	159	–
Total	25,067	5,561

11. FINANCE INCOME AND COSTS

	Six months ended 30 June	
	2025 RMB'000 (Unaudited)	2024 RMB'000 (Unaudited)
Bank interest income	2,943	2,143
Foreign exchange differences, net	4,539	429
Finance income	7,482	2,572
Interest on bank borrowings	(13,827)	(13,817)
Interest on lease liabilities	(442)	(648)
Bank charges	(658)	(633)
	(14,927)	(15,098)
Less: Amount capitalized	–	6,633
Finance costs	(14,927)	(8,465)
Finance costs, net	(7,445)	(5,893)

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

12. INCOME TAX EXPENSE

No current income tax was provided for the six months ended 30 June 2025 (30 June 2024: nil) as there was no estimated assessable profit.

The Group's principal applicable taxes and tax rates are as follows:

Shanghai Miracogen Inc. ("Miracogen Shanghai") renewed its qualification as a High and New Technology Enterprise ("HNTe") under the relevant PRC laws and regulations in 2023. Accordingly, it was entitled to a preferential corporate income tax rate of 15% on its estimated assessable profits for a three-year period since then.

Lepu (Beijing) Biopharma Co., Ltd. ("Lepu Beijing") renewed its qualification as a HNTe under the relevant PRC laws and regulations in 2024. Accordingly, it was entitled to a preferential corporate income tax rate of 15% on its estimated assessable profits for a three-year period since then.

CtM Bio Co., Ltd. ("CtM Bio") was qualified as a HNTe under the relevant PRC laws and regulations on 12 December 2023. Accordingly, it was entitled to a preferential corporate income tax rate of 15% on its estimated assessable profits for a three-year period since then.

The Company and the Company's other subsidiaries which were established and operate in Mainland China are subject to the PRC corporate income tax at the rate of 25%.

13. EARNINGS/(LOSS) PER SHARE

(a) Basic earnings/(loss) per share

Basic earnings/(loss) per share is calculated by dividing:

- the profit/(loss) attributable to the owners of the Company, excluding any costs of servicing equity other than ordinary shares.
- by the weighted average number of ordinary shares outstanding during the interim period.

	Six months ended 30 June	
	2025 (Unaudited)	2024 (Unaudited)
Profit/(loss) for the period and attributable to owners of the Company (in RMB'000)	41,745	(192,430)
Weighted average number of ordinary shares in issue (in thousands)	1,710,615	1,670,129
Basic earnings/(loss) per share (in RMB)	0.02	(0.12)

(b) Diluted earnings/(loss) per share

Diluted earnings/(loss) per share presented is the same as the basic earnings per share as there were no potentially dilutive ordinary shares in issue during the six months ended 30 June 2025 and 2024.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

14. PROPERTY, PLANT AND EQUIPMENT

	Buildings and facilities RMB'000	Equipment and instruments RMB'000	Office equipment and furniture RMB'000	Motor vehicles RMB'000	Leasehold improvements and antibody purification resin RMB'000	Construction- in progress RMB'000	Total
At 31 December 2024							
Cost	660,233	334,253	43,433	951	118,914	22,381	1,180,165
Accumulated depreciation	(12,004)	(109,656)	(23,109)	(830)	(104,460)	–	(250,059)
Net carrying amount	648,229	224,597	20,324	121	14,454	22,381	930,106
Six months ended 30 June 2025							
Opening net carrying amount	648,229	224,597	20,324	121	14,454	22,381	930,106
Additions	42,238	837	155	–	686	57	43,973
Transfer upon completion	–	591	–	–	–	(591)	–
Depreciation charge	(9,677)	(15,390)	(2,418)	(25)	(1,978)	–	(29,488)
Disposal	–	(3,077)	–	–	–	–	(3,077)
Closing net carrying amount	680,790	207,558	18,061	96	13,162	21,847	941,514
At 30 June 2025 (Unaudited)							
Cost	702,471	331,659	43,588	951	119,600	21,847	1,220,116
Accumulated depreciation	(21,681)	(124,101)	(25,527)	(855)	(106,438)	–	(278,602)
Net carrying amount	680,790	207,558	18,061	96	13,162	21,847	941,514

As at 30 June 2025, certain of the Group's property, plant and equipment located in Shanghai ("Shanghai Biological Park") with carrying amount of approximately RMB680,790,000 (31 December 2024: RMB648,229,000) had been pledged to the bank as security for a bank borrowings of RMB230,173,000 (31 December 2024: RMB260,261,000) (Note 22).

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

15. RIGHT-OF-USE ASSETS

	Land use rights RMB'000	Leased properties RMB'000	Total RMB'000
At 31 December 2024			
Cost	128,817	57,262	186,079
Accumulated depreciation	(36,290)	(28,857)	(65,147)
Net carrying amount	92,527	28,405	120,932
Six months ended 30 June 2025			
Opening net carrying amount	92,527	28,405	120,932
Depreciation charge	(3,222)	(7,102)	(10,324)
Closing net carrying amount	89,305	21,303	110,608
At 30 June 2025 (Unaudited)			
Cost	128,817	57,262	186,079
Accumulated depreciation	(39,512)	(35,959)	(75,471)
Net carrying amount	89,305	21,303	110,608

As at 30 June 2025, land use rights with carrying amounts of approximately RMB48,565,000 (31 December 2024: RMB50,421,000) had been pledged to the bank as security for a bank borrowings of RMB230,173,000(31 December 2024: RMB260,261,000) (Note 22).

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

16. INTANGIBLE ASSETS

	Capitalised product development costs RMB'000	Goodwill RMB'000	Intellectual properties RMB'000	Software RMB'000	Total RMB'000
At 31 December 2024					
Cost	32,327	52,636	531,582	1,543	618,088
Accumulated amortisation	–	–	(182,539)	(299)	(182,838)
Net carrying amount	32,327	52,636	349,043	1,244	435,250
Six months ended 30 June 2025					
Opening net carrying amount	32,327	52,636	349,043	1,244	435,250
Additions	39,097	–	3,601	–	42,698
Amortisation charge	–	–	(15,306)	(77)	(15,383)
Closing net carrying amount	71,424	52,636	337,338	1,167	462,565
At 30 June 2025 (Unaudited)					
Cost	71,424	52,636	535,183	1,543	660,786
Accumulated amortisation	–	–	(197,845)	(376)	(198,221)
Net carrying amount	71,424	52,636	337,338	1,167	462,565

During the six months ended 30 June 2025, the Group capitalised product development costs of RMB39,097,000 (six months ended 30 June 2024: RMB6,644,000) for PD-1 products which has satisfied the criteria of capitalisation.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

17. INVESTMENTS ACCOUNTED FOR USING THE EQUITY METHOD

The amounts recognised in the interim condensed consolidated financial position are as follows:

	As at 30 June 2025 RMB'000 (Unaudited)	As at 31 December 2024 RMB'000 (Audited)
Associates	108,425	114,073

The amounts recognised in the interim condensed consolidated statement of profit or loss and other comprehensive income are as follows:

	Six months ended 30 June 2025 RMB'000 (Unaudited)	2024 RMB'000 (Unaudited)
Associates	(6,234)	(7,037)

Movements in the Group's interest in the associates are as follows:

	Six months ended 30 June 2025 RMB'000 (Unaudited)	2024 RMB'000 (Unaudited)
At beginning of the period	114,073	126,685
Share of loss of investments	(6,234)	(7,037)
Share of other comprehensive income	(6)	806
Share of other reserves	592	2,198
At end of the period	108,425	122,652

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

18. OTHER RECEIVABLES, PREPAYMENTS AND DEPOSITS

	As at 30 June	As at 31 December
	2025 RMB'000 (Unaudited)	2024 RMB'000 (Audited)
Value added tax recoverable	38,947	42,093
Deposits	3,521	13,761
Prepayments for:		
– property, plant and equipment	26,524	26,020
– clinical study related expenses	36,159	63,889
– listing expenses	–	1,047
Others	509	52
	105,660	146,862
Less: loss allowance for other receivables and deposits	(63)	(60)
	105,597	146,802
Less: non-current portion (a)	(34,041)	(34,816)
Current portion	71,556	111,986

- (a) The non-current portion of other receivables, prepayments and deposits include prepayments to suppliers for property, plant and equipment, value added tax recoverable that could not be utilised in the next 12 months and deposits that are not expected to be refunded in the next 12 months which are as follows.

	As at 30 June	As at 31 December
	2025 RMB'000 (Unaudited)	2024 RMB'000 (Audited)
Non-current portion		
Value added tax recoverable	4,781	6,060
Prepayments for property, plant and equipment	26,524	26,020
Deposits	2,736	2,736
Total	34,041	34,816

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

19. TRADE RECEIVABLES

	As at 30 June	As at 31 December
	2025 RMB'000 (Unaudited)	2024 RMB'000 (Audited)
Trade receivables	50,172	46,232
Less: Loss allowance	(423)	(411)
Total	49,749	45,821

The Group grants a credit term of 30 days to its customers. At 30 June 2025 and 31 December 2024, the ageing analysis of the trade receivables (net of loss allowance) based on the invoice date is as follows:

	As at 30 June	As at 31 December
	2025 RMB'000 (Unaudited)	2024 RMB'000 (Audited)
0 to 30 days	49,682	44,007
31 to 60 days	–	1,716
61 to 90 days	–	98
Over 90 days	67	–
Total	49,749	45,821

20. FINANCIAL ASSETS AT FVTPL

	As at 30 June	As at 31 December
	2025 RMB'000 (Unaudited)	2024 RMB'000 (Audited)
Unlisted equity investment	63,628	63,628

21. SHARE CAPITAL

	Number of shares	Nominal value of shares RMB'000
Authorised issued and fully paid		
At 1 January 2025 and at 30 June 2025 (Unaudited)	1,710,614,838	1,710,615
At 1 January 2024	1,659,444,838	1,659,445
Issuance of shares	51,170,000	51,170
At 30 June 2024 (Unaudited)	1,710,614,838	1,710,615

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

22. BORROWINGS

	As at 30 June	As at 31 December
	2025 RMB'000 (Unaudited)	2024 RMB'000 (Audited)
Current		
Bank borrowings, non-secured	566,614	478,150
Bank borrowings, secured (a)	70,173	60,261
Non-current		
Bank borrowings, non-secured	80,337	55,940
Bank borrowings, secured (a)	160,000	200,000
Total	877,124	794,351

As at 30 June 2025 and 31 December 2024, the Group's borrowings were repayable as follows:

	As at 30 June	As at 31 December
	2025 RMB'000 (Unaudited)	2024 RMB'000 (Audited)
Within 1 year	636,787	538,411
Between 1 and 2 years	180,337	135,940
Between 2 and 5 years	60,000	120,000
Total	877,124	794,351

- (a) Details of the assets of the Group that have been pledged to bank as the security for the bank borrowings as at 30 June 2025 and 31 December 2024 are set out in Note 14 and 15. The borrowings bear interest at a floating rate ranging from 2.90% to 3.00% per annum. (31 December 2024: from 3.45% to 3.80%). Interest is payable quarterly. The principal amounts for the borrowings are payable in batches from 20 June 2022 to 1 September 2027.

The fair value of borrowings approximated their carrying amounts as at 30 June 2025 and 31 December 2024 as the borrowings carried interests which were benchmarked against rates announced by the People's Bank of China from time to time.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

23. DEFERRED INCOME TAX

The deferred income tax assets and liabilities are mainly due from the acquisition of subsidiaries, and the amount of offsetting deferred income tax assets and liabilities as at 30 June 2025 is RMB10,134,000 (31 December 2024: RMB11,490,000).

(a) Deferred tax assets

	Six months ended 30 June	
	2025 RMB'000 (Unaudited)	2024 RMB'000 (Unaudited)
At beginning of the period	11,490	14,201
Charged to profit or loss	(1,356)	(1,357)
At end of the period	10,134	12,844

(b) Deferred tax liabilities

	Six months ended 30 June	
	2025 RMB'000 (Unaudited)	2024 RMB'000 (Unaudited)
At beginning of the period	(49,177)	(51,888)
Credited to profit or loss	1,356	1,357
At end of the period	(47,821)	(50,531)

For presentation purposes, certain deferred tax assets and liabilities have been offset in the statement of financial position. The following is an analysis of the deferred tax balances of the Group for financial reporting purposes:

	As at 30 June	As at 31 December
	2025 RMB'000 (Unaudited)	2024 RMB'000 (Audited)
Net deferred tax assets recognised in the consolidated statement of financial position	—	—
Net deferred tax liabilities recognised in the consolidated statement of financial position	(37,687)	(37,687)

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

24. FINANCIAL LIABILITIES AT FVTPL

	As at 30 June	As at 31 December
	2025 RMB'000 (Unaudited)	2024 RMB'000 (Audited)
Variable consideration payable arising from acquisition of 40% equity of Taizhou Hanzhong Biotechnology Co., Ltd. from non-controlling interests	280,069	263,112
Less: current portion	(41,765)	(30,845)
Non-current portion	238,304	232,267

The movements of financial liabilities at FVTPL for the six months ended 30 June 2025 and 2024 are set out below:

	Six months ended 30 June	
	2025 RMB'000 (Unaudited)	2024 RMB'000 (Unaudited)
Opening balance	263,112	272,625
Change in fair value	16,957	124
Closing balance	280,069	272,749

25. TRADE PAYABLES

The aging analysis of the trade payables based on their respective issue dates are as follows:

	As at 30 June	As at 31 December
	2025 RMB'000 (Unaudited)	2024 RMB'000 (Audited)
Less than 1 year	211,128	211,469
Between 1 and 2 years	15,077	24,666
Total	226,205	236,135

Trade payables are unsecured and are usually settled within 30 days from the date of initial recognition.

The carrying amounts of trade payables are considered to be the same as their fair values, due to their short-term nature.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

26. COMMITMENTS

(a) Capital commitments

Capital expenditures contracted for at the balance sheet dates but not yet incurred is as follows:

	As at 30 June	As at 31 December
	2025 RMB'000 (Unaudited)	2024 RMB'000 (Audited)
Property, plant and equipment	448,663	456,840

(b) Operating lease commitments

At the end of the reporting period, the Group's commitments for future minimum lease payments under non-cancellable short-term leases are as follows:

	As at 30 June	As at 31 December
	2025 RMB'000 (Unaudited)	2024 RMB'000 (Audited)
No later than 1 year	528	528

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

27. RELATED PARTY TRANSACTIONS

The directors are of the view that the following parties are excluding subsidiaries and associates, are other related parties that had transactions or balances with the Group:

Name	Relationship with the Group
Beijing Pufeng Medical Management Co., Ltd. (北京普峰醫療管理有限公司)	A subsidiary of an entity of which the director is a close family member of the director of the Company
Beijing Volt Technology Co., Ltd. (北京伏爾特技術有限公司)	A subsidiary of an entity of which the director is a close family member of the director of the Company
Lepu Pharmaceuticals, Inc. (樂普藥業股份有限公司)	Controlled by a shareholder which has significant influence over the Group
Beijing Aipuyi Medical Testing Center Co. Ltd. (北京愛普益醫學檢驗中心有限公司)	Controlled by a shareholder which has significant influence over the Group
Lepu Ruikang (Beijing) Technology Co., Ltd. (樂普睿康(北京)科技有限公司)	Controlled by a shareholder which has significant influence over the Group
Beijing Lepu Hushengtang Network Technology Co., Ltd. (北京樂普護生堂網絡科技有限公司)	Controlled by a shareholder which has significant influence over the Group
Lepu Medical Technology (Beijing) Co., Ltd. (樂普診斷科技股份有限公司)	Controlled by a shareholder which has significant influence over the Group
CG Oncology, Inc.	An entity of which the director is a close family member of the director of the Company
KYM	An associate of the entity

The following significant transactions were carried out between the Group and its related parties during the reporting period. In the opinion of the directors of the Company, the related party transactions were carried out in the normal course of business and at terms negotiated between the Group and the respective related parties.

27.1 Transactions with other related parties

(a) Purchase and sale of raw materials and various services

	Six months ended 30 June	
	2025 RMB'000 (Unaudited)	2024 RMB'000 (Unaudited)
Licensing income from associate	13,992	20,678
CDMO services income from related parties	6,258	17,769
Assets disposal income from a related party	3,968	–
Purchase of professional services from related parties	799	1,104
Purchase of raw materials from related parties	265	16

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

27. RELATED PARTY TRANSACTIONS (CONTINUED)

27.1 Transactions with other related parties (Continued)

(b) Rental services

	Type of leased asset	Rental expenses for short-term leases and leases of low-value assets treated in a simplified manner RMB'000	Settlement of lease liabilities RMB'000
2025			
Rental services from a related party	Production Factory	286	4,547
2024			
Rental services from a related party	Production Factory	242	4,443

27.2 Balances with related parties

	As at 30 June 2025 RMB'000 (Unaudited)	As at 31 December 2024 RMB'000 (Audited)
Balances due from related parties		
Prepayment to a related party	1,520	1,520
Other receivables from a related party	1,616	1,390
Trade receivables from a related party	2,187	5,180
Balances due to related parties		
Trade payables to related parties	209	207
Other payables and accruals to related parties	4,057	9,544
Lease liabilities to a related party	28,751	33,013

As at 30 June 2025 and 31 December 2024, there was no any non-trade nature balance with related parties, all balances with related parties were non-interest bearing and trade in nature, and their fair values approximated their carrying amounts due to their short maturities.

NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

27. RELATED PARTY TRANSACTIONS (CONTINUED)

27.3 Key management compensation

Key management includes executive directors, supervisors and senior management. The compensation paid or payable to key management personnel is shown below:

	Six months ended 30 June	
	2025 RMB'000 (Unaudited)	2024 RMB'000 (Unaudited)
Salaries, bonus and other allowances	2,821	4,267
Pension costs – defined contribution plans	141	137
Other social security costs, housing benefits, and other employee benefits	178	172
Share-based payment expenses	–	848
Total	3,140	5,424

28. DIVIDEND

No dividend has been paid or declared by the Company or companies comprising the Group during the six months ended 30 June 2025 and 2024.

29. EVENTS OCCURRING AFTER THE REPORTING PERIOD

On 11 July 2025, the Company had completed a placing of 93,825,000 new H shares with a par value of RMB1.00 each at the price of HK\$5.02 per H Share (the “**Placing**”). The gross proceeds from the Placing amounted to approximately HK\$471,002,000 (equivalent to RMB430,138,000). The number of total issued shares of the Company has increased from 1,710,614,838 shares to 1,804,439,838 shares upon completion of the Placing.

On 1 August 2025, the Company entered into a licensing transaction agreement with Excalipoint Cayman and Excalipoint Shanghai (collectively, “**Excalipoint**”), upon which, Excalipoint will obtain the exclusive rights to develop and commercialize the target products globally, while the Company shall receive (i) an upfront payment in cash of US\$10 million in aggregate and ordinary shares to be issued by Excalipoint Cayman representing 10% of the enlarged issue capital of Excalipoint Cayman, (ii) development and commercial milestone payments in cash of up to US\$847.5 million in aggregate, and (iii) sales royalties at a tiered rate.

DEFINITIONS AND GLOSSARY OF TECHNICAL TERMS

"AACR"	American Association for Cancer Research
"actual controller"	the individual or entity that can control a company by way of investment
"ADC"	antibody drug conjugate, a class of biopharmaceutical drugs that combine monoclonal antibodies specific to surface antigens present on particular tumor cells with highly potent antitumor small molecule agents linked via a chemical linker
"ASCO"	American Society of Clinical Oncology
"associate(s)"	has the meaning ascribed to it under the Listing Rules
"AstraZeneca"	AstraZeneca AB, a global pharmaceutical company which, to the best knowledge and belief of the Company, is independent of and not connected with the Company and its connected persons (as defined under the Listing Rules)
"ArriVent"	ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company listed on the Nasdaq Global Market (ticker symbol: AVBP) which, to the best knowledge and belief of the Company, is independent of and not connected with the Company and its connected persons (as defined under the Listing Rules)
"Audit Committee"	the audit committee of the Board
"Authorized Representative(s)"	the authorized representative(s) of the Company
"B cell"	a type of white blood cell that differs from other types of lymphocytes by expressing B cell receptors on its surface, and responsible for producing antibodies
"Bacillus Calmette – Guerin" or "BCG"	a type of bacteria that causes a reaction in a patient's immune system that can destroy cancer cells located in the lining of the bladder. It is also widely used as a vaccine against tuberculosis
"BC"	breast cancer
"BD"	business development
"Beijing Houde Yimin"	Beijing Houde Yimin Investment Management Co., Ltd. (北京厚德義民投資管理有限公司), a limited liability company incorporated in the PRC on August 17, 2009

DEFINITIONS AND GLOSSARY OF TECHNICAL TERMS

"Board of Directors" or "Board"	the board of Directors of the Company
"BTD"	Breakthrough Therapy Designation
"CC"	cervical cancer
"CD20"	a B-lymphocyte antigen that is expressed on the surface of B cells, starting at the pre-B cell stage and also on mature B cells in the bone marrow and in the periphery
"CDE"	Center for Drug Evaluation* (藥品審評中心) of the NMPA
"CDMO"	contract development and manufacturing organization, a pharmaceutical company that develops and manufactures drugs for other pharmaceutical companies on a contractual basis
"CDX"	cell derived xenograft
"CG Oncology"	CG Oncology, Inc. (previously known as Cold Genesys, Inc.), a clinical-stage immuno-oncology company headquartered in the U.S., of which Lepu Medical holds approximately 7.73% equity interest through Lepu Holdings Limited, a company wholly owned by Lepu Medical, and Ms. Pu Jue (蒲珏) serves as a director
"chemotherapy"	a category of cancer treatment that uses one or more anti-cancer small molecule chemical agents as part of its standardized regimen
"China", "Mainland China" or the "PRC"	the People's Republic of China excluding, for the purpose of this interim report, Hong Kong, Macau Special Administrative Region and Taiwan
"CLDN18.2"	Claudin 18.2, a highly specific tissue junction protein for gastric tissue
"CMC"	chemistry, manufacturing, and controls processes in the development, licensure, manufacturing, and ongoing marketing of pharmaceutical products
"combination therapy"	a treatment modality that combines two or more therapeutic agents
"Company" or "our Company"	Lepu Biopharma Co., Ltd. (樂普生物科技股份有限公司), a joint stock company incorporated in the PRC with limited liability, the H Shares of which are listed on the Stock Exchange (Stock code: 2157)
"Companies Ordinance"	the Companies Ordinance (Chapter 622 of the Laws of Hong Kong), as amended, supplemented or otherwise modified from time to time

DEFINITIONS AND GLOSSARY OF TECHNICAL TERMS

“connected person(s)”	has the meaning ascribed to it under the Listing Rules
“Controlling Shareholder”	has the meaning ascribed under the Listing Rules and unless the context otherwise requires, refers to Dr. Pu Zhongjie
“Core Product(s)”	has the meaning ascribed to it in Chapter 18A of the Listing Rules; for purposes of this interim report, our core products include MRG003, MRG002 and PUYOUHENG (Pucotenlimab Injection)
“Corporate Governance Code”	the Corporate Governance Code as set out in Appendix C1 to the Listing Rules
“CR”	complete response, the disappearance of all signs of cancer in response to treatment
“CSCO”	Chinese Society of Clinical Oncology
“CSGO”	Chinese Society of Gynecological Oncology
“DCR”	disease control rate, the total proportion of patients who demonstrate a response to treatment, equal to the sum of complete responses (CR), partial responses (PR) and stable disease (SD)
“Director(s)”	the director(s) of the Company
“DLBCL”	diffuse large B cell lymphoma
“Domestic Share(s)”	ordinary share(s) in the share capital of the Company, with a nominal value of RMB1.00 each, which are subscribed for and paid up in RMB and are unlisted Shares which are currently not listed or traded on any stock exchange, and the term “Domestic Shareholder(s)” shall be construed accordingly
“EGFR”	epidermal growth factor receptor
“ESMO”	European Society for Medical Oncology
“Excalipoint”	Excalipoint Cayman and Excalipoint Biotechnology (Shanghai) Co., Limited (艾科聯生物科技(上海)有限公司), an indirect wholly-owned subsidiary of Excalipoint Cayman
“Excalipoint Cayman”	Excalipoint Therapeutics Inc., a company incorporated in the Cayman Islands
“FDA”	Food and Drug Administration of the United States

DEFINITIONS AND GLOSSARY OF TECHNICAL TERMS

"first-line"	with respect to any disease, the first line therapy, which is the treatment regimen or regimens that are generally accepted by the medical establishment for initial treatment. It is also called primary treatment or therapy
"FISH"	fluorescence in situ hybridization, a test that maps the genetic material in human cells, including specific genes or portions of genes
"FTD"	Fast Track Designation
"GC"	gastric cancer
"GEJ"	gastroesophageal junction
"GI cancer"	gastrointestinal cancer
"GLP-1"	glucagon-like peptide-1
"GMP"	a system for ensuring that products are consistently produced and controlled according to quality standards, which is designed to minimize the risks involved in any pharmaceutical production that cannot be eliminated through testing the final product. It is also the practice required in order to conform to the guidelines recommended by agencies that control the authorization and licensing of the manufacture and sale of pharmaceutical products
"GPC-3"	Glypican-3
"Group", "we", "us" or "our"	the Company and its subsidiaries
"H Share(s)"	overseas listed foreign invested ordinary share(s) in the ordinary share capital of the Company, with a nominal value of RMB1.00 each, listed on the Main Board of the Stock Exchange, and the term "H Shareholder(s)" shall be construed accordingly
"HCC"	hepatocellular carcinoma
"HER2"	human epidermal growth factor receptor 2
"HER2-expressing"	HER2 status of tumor cells identified with a test score of IHC 1+ or above
"HER2 over-expressing" or "HER2-positive"	HER2 status of tumor cells identified with a test score of either IHC 3+ or (IHC 2+ plus FISH (or ISH)+)
"HK\$" or "Hong Kong dollars"	Hong Kong dollars, the lawful currency of Hong Kong

DEFINITIONS AND GLOSSARY OF TECHNICAL TERMS

“HNSCC”	head and neck squamous cell carcinoma
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC
“H Share Registrar”	Computershare Hong Kong Investor Services Limited
“IFRS”	International Financial Reporting Standards, which include standards, amendments and interpretations issued by the International Accounting Standards Board
“IgG”	human immunoglobulin G, the most common antibody type found in blood circulation that plays an important role in antibody-based immunity against invading pathogens
“IHC”	immunohistochemistry, the most common application of immunostaining. It involves the process of selectively identifying antigens in cells of a tissue section by exploiting the principle of antibodies binding specifically to antigens in biological tissues
“IND”	investigational new drug or investigational new drug application, also known as clinical trial application in China or the U.S.
“Intellectual Property Assignment and License Agreement”	the framework agreement in respect of the transfer or grant certain rights and interests over the Target Products to, among other things, allow Excalipoint to conduct R&D, register, manufacture, and commercialize the Target Products. entered into between the Company and Excalipoint on August 1, 2025
“Keymed”	Keymed Bioscience (Chengdu) Co., Ltd. (康諾亞生物醫藥科技(成都)有限公司), a limited liability company incorporated in the PRC on September 1, 2016, which is a third-party biotechnology company focusing on the inhouse discovery and development of innovative biological therapies in the autoimmune and oncology therapeutic areas
“KOL”	key opinion leader, who are professionals that influence their peers’ medical practice, including but not limited to prescribing behavior
“KYM”	KYM Biosciences Inc., a Delaware corporation and a joint venture formed in the U.S. by Keymed and our Group
“Latest Practicable Date”	September 12, 2025, being the latest practicable date prior to the printing of this interim report for the purpose of ascertaining certain information contained in this interim report

DEFINITIONS AND GLOSSARY OF TECHNICAL TERMS

"Lepu Medical"	Lepu Medical Technology (Beijing) Co., Ltd. (樂普(北京)醫療器械股份有限公司), a joint stock company incorporated in the PRC on June 11, 1999 and listed on the Shenzhen Stock Exchange (stock code: 300003), and the promoter of the Company
"License Agreement for CMG901"	a global exclusive out-license agreement entered into by KYM and AstraZeneca on February 23, 2023
"License Agreement for MRG0007"	an exclusive out-license agreement entered into by the Company and ArriVent on January 22, 2025
"Listing Rules"	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, as amended, supplemented or otherwise modified from time to time
"mAb"	monoclonal antibody, an antibody generated by identical cells that are all clones of the same parent cell
"Macau"	the Macau Special Administrative Region of the PRC
"Main Board"	the Main Board of the Stock Exchange
"metastatic"	in reference to any disease, including cancer, disease producing organisms or of malignant or cancerous cells transferred to other parts of the body by way of the blood or lymphatic vessels or membranous surfaces
"Miracogen HK"	Miracogen Limited, a limited liability company established under the laws of Hong Kong and a special purpose investment vehicle wholly-owned by Miracogen Inc., which in turn is a company wholly-owned by Dr. Hu Chaohong, our executive Director and co-chief executive officer of our Company during the Reporting Period
"Miracogen Shanghai"	Shanghai Miracogen Inc. (上海美雅珂生物技術有限責任公司), a limited liability company incorporated in the PRC on January 27, 2014, and a wholly owned subsidiary of the Company
"MMAE"	monomethyl auristatin E, a potent tubulin binder with a half maximal inhibitory concentration (IC50) in the subnanomolar range
"Model Code"	the Model Code for Securities Transactions by Directors of Listed Issuers as set out in Appendix C3 to the Listing Rules
"mOS"	median overall survival

DEFINITIONS AND GLOSSARY OF TECHNICAL TERMS

"mPFS"	median progression free survival
"MRCT"	multi-regional clinical trial
"MSI-H/dMMR"	high levels of microsatellite instability/deficient mismatch repair
"NDA"	new drug application
"NHL"	non-Hodgkin's lymphoma
"Ningbo Houde Yimin"	Ningbo Houde Yimin Information Technology Co., Ltd. (寧波厚德義民信息科技有 限公司), a limited liability company incorporated in the PRC on March 29, 2017, and the promoter of the Company
"NK Cell"	natural killer cell, a kind of cells that play important roles in immunity against viruses and in the immune surveillance of tumors
"NMIBC"	non-muscle invasive bladder cancer
"NMPA"	中國國家藥品監督管理局(National Medical Products Administration of the PRC*)
"Nomination Committee"	the nomination committee of the Board
"NPC"	nasopharyngeal cancer
"ODD"	Orphan-drug Designation
"ORR"	overall response rate
"PC"	pancreatic cancer
"PD-1"	programmed cell death protein 1, an immune checkpoint receptor expressed on T cells, B cells and macrophages
"PD-L1"	PD-1 ligand 1, which is a protein on the surface of a normal cell or a cancer cell that binds to its receptor, PD-1, on the surface of the T cell that causes the T cell to turn off its ability to kill the cancer cell
"PD-L2"	PD-1 ligand 2, which is a protein on the surface of a normal cell or a cancer cell that attaches to certain proteins on the surface of the T cell that causes the T cell to turn off its ability to kill the cancer cell

DEFINITIONS AND GLOSSARY OF TECHNICAL TERMS

"PDX"	patient derived xenografts, models of cancer where the tissue or cells from a patient's tumor are implanted into an immunodeficient mouse
"PFS"	progression-free-survival
"Pgp"	a drug transporter which plays important roles in multidrug resistance and drug pharmacokinetics
"Phase I clinical trial(s)" or "Phase I clinical study(ies)"	study in which a drug is introduced into healthy human subjects or patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion, and if possible, to gain an early indication of its effectiveness
"Phase II clinical trial(s)" or "Phase II clinical study(ies)"	study in which a drug is administered to a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases, and to determine dosage tolerance and optimal dosage
"Phase III clinical trial(s)" or "Phase III clinical study(ies)"	study in which a drug is administered to an expanded patient population generally at geographically dispersed clinical trial sites, in well-controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to provide adequate information for the labelling of the product
"placebo"	any dummy medical treatment administered to the control group in a controlled clinical trial in order that the specific and non-specific effects of the experimental treatment can be distinguished
"PRC Legal Adviser"	Zhong Lun Law Firm, our legal adviser as to the laws of the PRC
"pre-clinical studies"	studies or programs testing a drug on non-human subjects, to gather efficacy, toxicity, pharmacokinetic and safety information and to decide whether the drug is ready for clinical trials
"registrational trial"	a clinical trial or study intended to provide evidence for a drug marketing approval
"Remuneration and Appraisal Committee"	the remuneration and appraisal committee of the Board
"Reporting Period"	the six months ended June 30, 2025
"RMB"	Renminbi, the lawful currency of the PRC

DEFINITIONS AND GLOSSARY OF TECHNICAL TERMS

"R/M"	recurrent/metastatic
"R&D"	research and development
"second-line"	with respect to any disease, the therapy or therapies that are tried when the first-line treatments do not work adequately
"SFO"	the Securities and Futures Ordinance, Chapter 571 of the Laws of Hong Kong, as amended, supplemented or otherwise modified from time to time
"Shanghai Lvyuan"	Lvyuan (Shanghai) Technology Co., Ltd. (律元(上海)科技有限公司), a limited liability company incorporated in the PRC on April 11, 2019, and the promoter of our Company
"Shanghai Stock Exchange"	the Shanghai Stock Exchange (上海證券交易所)
"Shareholder(s)"	holder(s) of the Shares
"Share Purchase Agreement"	the agreement in respect of issuance and subscription of the shares of Excalipoint Cayman, entered into by, among others, Innocube, Dr. Fang and the Excalipoint Companies on August 1, 2025
"Share(s)"	shares in the share capital of the Company, with a nominal value of RMB1.00 each, comprising the Domestic Shares, and H Shares
"Shenzhen Stock Exchange"	the Shenzhen Stock Exchange (深圳證券交易所)
"solid tumors"	an abnormal mass of tissue that usually does not contain cysts or liquid areas. Solid tumors may be benign (not cancer), or malignant (cancer). Different types of solid tumors are named for the type of cells that form them
"Stock Exchange"	The Stock Exchange of Hong Kong Limited
"Strategy Committee"	the strategy committee of the Company
"subsidiaries"	has the meaning ascribed to it in section 15 of the Companies Ordinance
"substantial shareholder(s)"	has the meaning ascribed to it under the Listing Rules
"Supervisor(s)"	supervisor(s) of the Company
"Supervisory Committee"	the supervisory committee of the Company

DEFINITIONS AND GLOSSARY OF TECHNICAL TERMS

"T cell"	a lymphocyte of a type produced or processed by the thymus gland and actively participating in the immune response, which plays a central role in cell-mediated immunity. T cells can be distinguished from other lymphocytes, such as B cells and NK cells, by the presence of a T cell receptor on the cell surface
"TCR"	a protein complex found on the surface of T cells that is responsible for recognizing fragments of antigen as peptides bound to major histocompatibility complex molecules
"tissue factor" or "TF"	a protein encoded by the F3 gene, present in subendothelial tissue and leukocytes. Many cancer cells express high level of TF
"TNBC"	triple-negative breast cancer
"topoisomerase I inhibitor"	a chemical compound that blocks the action of type I topoisomerases
"UC"	urothelial cancer
"United States" or "the U.S."	the United States of America, its territories and possessions, any State of the United States, and the District of Columbia
"US\$"	United States dollars, the lawful currency of the United States
"vc linker"	valine-citrulline linker, which is adequately stable in blood circulation and cleaved effectively by the lysosomal cathepsin enzyme after the ADC is internalized and enters lysosome
"%"	per cent

* For identification purposes only